Integer (ITGR) 10-K 22 Feb 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2018	Feb. 15, 2019	Jun. 29, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Integer Holdings Corporation
Entity Central Index Key	1,114,483
Document Type	10-K
Document Period End Date	Dec. 28, 2018
Amendment Flag	false
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-28
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 2,050
Entity Common Stock, Shares Outstanding		32,516,677
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 28, 2018	Dec. 29, 2017
Current assets:
Cash and cash equivalents	$ 25,569,000	$ 37,341,000
Accounts receivable, net of allowance for doubtful accounts of $0.6 million and $0.5 million, respectively	185,501,000	194,845,000
Inventories	190,076,000	176,738,000
Prepaid expenses and other current assets	15,104,000	16,239,000
Disposal Group, Including Discontinued Operation, Assets, Current	0	106,746,000
Total current assets	416,250,000	531,909,000
Property, plant and equipment, net	231,269,000	235,180,000
Goodwill	832,338,000	839,870,000
Other intangible assets, net	812,338,000	862,873,000
Deferred income taxes	3,937,000	3,451,000
Other assets	30,549,000	30,428,000
Disposal Group, Including Discontinued Operation, Assets, Noncurrent	0	344,634,000
Total assets	2,326,681,000	2,848,345,000
Current liabilities:
Current portion of long-term debt	37,500,000	30,469,000
Accounts payable	57,187,000	64,551,000
Income taxes payable	9,393,000	5,904,000
Accrued expenses	60,490,000	60,376,000
Disposal Group, Including Discontinued Operation, Liabilities, Current	0	47,703,000
Total current liabilities	164,570,000	209,003,000
Long-term debt	888,007,000	1,578,696,000
Deferred income taxes	203,910,000	140,964,000
Other long-term liabilities	9,701,000	11,335,000
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent	0	14,966,000
Total liabilities	1,266,188,000	1,954,964,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 32,624,494 and 31,977,953 shares issued, respectively; 32,473,167 and 31,871,427 shares outstanding, respectively	33,000	32,000
Additional paid-in capital	691,083,000	669,756,000
Treasury stock, at cost, 151,327 and 106,526 shares, respectively	(8,125,000)	(4,654,000)
Retained earnings	344,498,000	176,068,000
Accumulated other comprehensive income	33,004,000	52,179,000
Total stockholders’ equity	1,060,493,000	893,381,000
Total liabilities and stockholders’ equity	$ 2,326,681,000	$ 2,848,345,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Current assets:
Allowance for doubtful accounts	$ 0.6	$ 0.5
Stockholders’ equity:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	32,624,494	31,977,953
Common stock, shares outstanding	32,473,167	31,871,427
Treasury stock, shares	151,327	106,526

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Income Statement [Abstract]
Income (Loss) from Continuing Operations, Per Basic Share	$ 1.46	$ 2.77	$ 0.81
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share	$ 3.76	$ (0.65)	$ (0.61)
Sales	$ 1,215,012	$ 1,136,080	$ 1,075,502
Cost of sales	852,347	782,070	737,823
Gross profit	362,665	354,010	337,679
Operating expenses:
Selling, general and administrative expenses	142,441	143,073	136,444
Research, development and engineering costs	48,604	48,850	47,899
Other operating expenses	16,065	36,438	60,413
Total operating expenses	207,110	228,361	244,756
Operating income	155,555	125,649	92,923
Interest expense	99,310	63,972	68,331
(Gain) loss on equity investments, net	(5,623)	1,565	833
Other (income) loss, net	752	10,853	(4,406)
Income from continuing operations before taxes	61,116	49,259	28,165
Provision (benefit) for income taxes	14,083	(37,828)	3,287
Net income (loss)	$ 167,964	$ 66,679	$ 5,961
Income (loss) from discontinued operations
Basic (in dollars per share)	$ 5.23	$ 2.12	$ 0.19
Income (Loss) from Continuing Operations, Per Diluted Share	1.44	2.72	0.80
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share	3.71	(0.64)	(0.61)
Diluted (in dollars per share)	$ 5.15	$ 2.08	$ 0.19
Weighted average shares outstanding:
Basic (in shares)	32,136	31,402	30,778
Diluted (in shares)	32,596	32,056	30,973
Comprehensive Income (Loss)
Net income (loss)	$ 167,964	$ 66,679	$ 5,961
Foreign currency translation gain (loss)	(19,925)	65,860	(19,269)
Net change in cash flow hedges, net of tax	16	2,243	2,478
Defined benefit plan liability adjustment, net of tax	302	76	(579)
Other comprehensive income (loss), net	(19,607)	68,179	(17,370)
Comprehensive income (loss)	148,357	134,858	(11,409)
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	47,033	87,087	24,878
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	188,313	(27,432)	(26,980)
Discontinued Operation, Tax Effect of Discontinued Operation	67,382	(7,024)	(8,063)
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	$ 120,931	$ (20,408)	$ (18,917)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Cash flows from operating activities:
Net income	$ 167,964	$ 66,679	$ 5,961
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	88,988	102,796	90,524
Debt related charges included in interest expense	49,110	10,911	7,278
Stock-based compensation	10,470	14,680	8,408
Non-cash (gain) loss on equity investments	(5,623)	2,965	1,495
Other non-cash losses	148	7,110	5,216
Deferred income taxes	61,126	(59,212)	(7,350)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	(194,965)	0	0
Changes in operating assets and liabilities:
Accounts receivable	9,289	(34,597)	(2,169)
Inventories	(16,094)	(986)	22,170
Prepaid expenses and other assets	8,527	4,854	(3,846)
Accounts payable	(94)	4,887	(1,127)
Accrued expenses	(11,756)	14,977	(13,935)
Income taxes payable	209	14,293	(7,093)
Net cash provided by operating activities	167,299	149,357	105,532
Cash flows from investing activities:
Acquisition of property, plant and equipment	(44,908)	(47,301)	(58,632)
Proceeds from sale of property, plant and equipment	1,379	472	347
Purchase of equity investments	(1,230)	(1,316)	(3,015)
Proceeds from Divestiture of Businesses	581,429	0	0
Other investing activities	0	209	(2,000)
Net cash provided by (used in) investing activities	536,670	(47,936)	(63,300)
Cash flows from financing activities:
Principal payments of long-term debt	(705,469)	(178,558)	(46,000)
Proceeds from issuance of long-term debt	5,000	50,000	57,000
Proceeds from Stock Options Exercised	12,409	19,324	2,821
Payment of debt issuance and redemption costs	(31,991)	(2,360)	(1,177)
Distribution of cash and cash equivalents to Nuvectra Corporation	0	0	(76,256)
Purchase of non-controlling interests	0	0	(6,818)
Payments Related to Tax Withholding for Share-based Compensation	(5,029)	(75)	(3,982)
Other financing activities	0	0	2,266
Net cash used in financing activities	(725,080)	(111,669)	(72,146)
Effect of foreign currency exchange rates on cash and cash equivalents	2,584	2,228	(448)
Net decrease in cash and cash equivalents	(18,527)	(8,020)	(30,362)
Cash and cash equivalents, beginning of year	44,096	52,116	82,478
Cash and cash equivalents, end of year	$ 25,569	$ 44,096	$ 52,116

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Jan. 01, 2016	$ 850,625	$ 31	$ 620,470	$ (3,100)	$ 231,854	$ 1,370
Balance, shares at Jan. 01, 2016		30,664		(63)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	5,961				5,961
Total other comprehensive income (loss)	(17,370)					(17,370)
Stock-based compensation	8,408		8,408
Net shares issued (acquired)	(1,164)	$ 0	1,570	$ (2,734)
Net shares issued under stock incentive plans, shares		395		(71)
Roll-over options issued in connection with acquisition	2,266		2,266
Spin-off of Nuvectra Corporation	(123,487)		5,241		(128,728)
Balance at Dec. 30, 2016	725,239	$ 31	637,955	$ (5,834)	109,087	(16,000)
Balance, shares at Dec. 30, 2016		31,059		(134)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	66,679				66,679
Total other comprehensive income (loss)	68,179					68,179
Stock-based compensation	14,680		14,680
Net shares issued (acquired)	19,114	$ 1	17,933	$ 1,180
Net shares issued under stock incentive plans, shares		919		27
Balance at Dec. 29, 2017	893,381	$ 32	669,756	$ (4,654)	176,068	52,179
Balance, shares at Dec. 29, 2017		31,978		(107)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect adjustment of the adoption of ASU 2016-09	(510)		(812)	$ 0	302	0
Net income	167,964
Total other comprehensive income (loss)	(19,607)					(19,607)
Accumulated Other Comprehensive Income, Reclassification To Earnings, Net of Tax	898
Tax Cuts And Jobs Act Of 2017 Reclassification From AOCI To Retained Earnings	0				466	(466)
Stock-based compensation	10,470		10,470
Net shares issued (acquired)	7,387	$ 1	10,857	$ (3,471)
Net shares issued under stock incentive plans, shares		646		(44)
Balance at Dec. 28, 2018	$ 1,060,493	$ 33	$ 691,083	$ (8,125)	$ 344,498	$ 33,004
Balance, shares at Dec. 28, 2018		32,624		(151)

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 28, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	(1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in the energy, military, and environmental markets. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries. On May 3, 2018, the Company entered into a definitive agreement to sell the Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC), and on July 2, 2018 completed the sale. On March 14, 2016, the Company completed the spin-off of a portion of its former QiG segment through a tax-free distribution of all of the shares of its former QiG Group, LLC subsidiary to the stockholders of Integer on a pro rata basis (the “Spin-off”). Refer to Note 2 “Discontinued Operations and Divestitures” for further details of these transactions. Basis of Presentation and Principles of Consolidation The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of Integer Holdings Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The results of operations of the AS&O Product Line are reported as discontinued operations in the Consolidated Statements of Operations for all periods presented and the related assets and liabilities associated with the discontinued operations are classified as held for sale in the Consolidated Balance Sheet as of December 29, 2017. The Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes, and, accordingly, cash flow amounts for discontinued operations are disclosed in Note 2 “Discontinued Operations and Divestitures.” All results and information in the consolidated financial statements are presented as continuing operations and exclude the AS&O Product Line unless otherwise noted specifically as discontinued operations. The Company’s results for periods prior to the Spin-off on March 14, 2016 include the financial and operating results of QiG Group, LLC, which did not qualify for presentation as discontinued operations. The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. The discontinued operations of the AS&O Product Line were reported in the Medical segment. Refer to Note 17 “Segment and Geographic Information,” for additional information on the Company’s reportable segments. Fiscal Year The Company utilizes a fifty-two or fifty-three week fiscal year ending on the Friday nearest December 31. Fiscal years 2018 , 2017 and 2016 consisted of fifty-two weeks and ended on December 28, 2018 , December 29, 2017 and December 30, 2016 , respectively. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting periods. Actual results could differ materially from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and accounts receivable are to four customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 17 “Segment and Geographic Information” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Trade Accounts Receivable and Allowance for Doubtful Accounts The Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains an allowance for those customer receivables that it does not expect to collect. The Company accrues its estimated losses from uncollectable accounts receivable to the allowance based upon recent historical experience, the length of time the receivable has been outstanding and other specific information as it becomes available. Provisions to the allowance for doubtful accounts are charged to current operating expenses. Actual losses are charged against this allowance when incurred. Inventories Inventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held as well as estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4 “Inventories” contains additional information on the Company’s inventory. Property, Plant and Equipment (“PP&E”) PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 12 - 30 years; machinery and equipment 3 - 10 years; office equipment 3 - 10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, if less. The cost of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. The Company also reviews its PP&E for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its fixed asset(s) exceeds the related undiscounted future cash flows. In cases where the carrying value of the Company's long-lived assets or asset groups (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. Note 5 “Property, Plant and Equipment, Net” contains additional information on the Company’s PP&E. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e . the “exit price”) in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) 820, Fair Value Measurements, establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows: Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment. Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market. Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations. Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 16 “Fair Value Measurements” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Acquisitions Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. All direct acquisition-related costs are expensed as incurred. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. Discontinued Operations In determining whether a group of assets which has been disposed of (or is to be disposed of) should be presented as a discontinued operation, the Company analyzes whether the group of assets being disposed of represented a component of the entity; that is, whether it had historic operations and cash flows that were clearly distinguished (both operationally and for financial reporting purposes). In addition, the Company considers whether the disposal represents a strategic shift that has or will have a major effect on the Company’s operations and financial results. The assets and liabilities of a discontinued operation held for sale, other than goodwill, are measured at the lower of carrying amount or fair value less cost to sell. When a portion of a goodwill reporting unit that constitutes a business is to be disposed of, the goodwill associated with that business is included in the carrying amount of the business based on the relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. The Company allocates interest to discontinued operations if the interest is directly attributable to the discontinued operations or is interest on debt that is required to be repaid as a result of the disposal transaction. Goodwill Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired and is assigned to one or more reporting units. The Company tests each reporting unit’s goodwill for impairment at least annually as of the last day of the fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. In conducting its goodwill test, the Company first performs a qualitative assessment, which requires that it consider events or circumstances including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, changes in strategy, changes in customers, changes in the Company’s stock price, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair values of its reporting units are greater than the carrying amounts, then the quantitative goodwill impairment test is not performed. If the qualitative assessment indicates that the quantitative analysis should be performed, the Company then evaluates goodwill for impairment by comparing the fair value of each of its reporting units to its carrying value, including the associated goodwill. To determine the fair values, the Company uses a weighted combination of the market approach based on comparable publicly traded companies and the income approach based on estimated discounted future cash flows. The cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. The Company completed its annual goodwill impairment test as of December 28, 2018 and determined, after performing a qualitative review of each reporting unit, that it is more likely than not that the fair value of each of its reporting units exceeds the respective carrying amounts. Accordingly, there was no indication of impairment and the quantitative goodwill impairment test was not performed. The Company does not believe that either of its reporting units are at risk for impairment. Other Intangible Assets Other intangible assets consist of purchased technology and patents, customer lists and trademarks. Definite-lived intangible assets are amortized on an accelerated or straight-line basis, which approximates the projected cash flows used to determine the fair value of those definite-lived intangible assets at the time of acquisition, as follows: purchased technology and patents 5 - 15 years; customer lists 7 - 20 years and other intangible assets 1 - 10 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized. The Company expenses the costs incurred to renew or extend the term of intangible assets. The Company reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) The Company assesses its indefinite-lived intangible assets for impairment periodically to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived intangible asset to its carrying value. The fair value is determined using the income approach. Refer to Note 6 “Goodwill and Other Intangible Assets, Net” for further details of the Company’s goodwill and other intangible assets. Equity Investments The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other Assets on the Consolidated Balance Sheets. Equity investments are measured and recorded as follows: • Non-marketable equity securities are equity securities without readily determinable fair value are measured and recorded at fair value with changes in fair value recognized within net income. The Company has elected the practicability exception to use an alternative that measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. Prior to fiscal 2018, these securities were accounted for using the cost method of accounting, measured at cost less other-than-temporary impairment. • Equity method investments are equity securities in investees the Company does not control but over which it has the ability to exercise influence. Equity method investments are measured at cost minus impairment, if any, plus or minus our share of equity method investee income or loss. Realized and unrealized gains and losses resulting from changes in fair value or the sale of these equity investments is recorded through (Gain) Loss on Equity Investments, Net. The carrying value of the Company’s non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities by the same issuer. Determining whether an observed transaction is similar to a security within the Company’s portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of the Company’s equity securities as a result of observable price changes requires quantitative assessments of the fair value of these securities using various valuation methodologies and involves the use of estimates. Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. The Company’s quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative factors considered include the investee's financial condition and business outlook, market for technology, operational and financing cash flow activities, technology and regulatory approval progress, and other relevant events and factors affecting the investee. When indicators of impairment exist, quantitative assessments of the fair value of the Company’s non-marketable equity investments are prepared. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. • Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security's fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. Prior to 2018, non-marketable equity securities were tested for impairment using the other-than-temporary impairment model. • Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and the Company’s ability and intent to hold the investment for a sufficient period of time to allow for recovery. The Company has determined that its investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant. Refer to Note 16 “Fair Value Measurements” for additional information on the Company’s equity investments. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Debt Issuance Costs and Discounts Debt issuance costs and discounts associated with the issuance of debt by the Company are deferred and amortized over the lives of the related debt. Debt issuance costs incurred in connection with the Company’s issuance of its revolving credit facility are classified within Other Assets and amortized to Interest Expense on a straight-line basis over the contractual term of the credit facility. Debt issuance costs and discounts related to the Company’s term-debt are recorded as a reduction of the carrying value of the related debt and are amortized to Interest Expense using the effective interest method over the period from the date of issuance to the put option date (if applicable) or the maturity date, whichever is earlier. The amortization of debt issuance costs and discounts are included in Debt Related Charges Included in Interest Expense in the Consolidated Statements of Cash Flows. Upon prepayment of the related debt, the Company accelerates the recognition of a proportionate amount of the costs as refinancing or extinguishment of debt. Note 8 “Debt” contains additional information on the Company’s debt issuance costs and discounts. Income Taxes The consolidated financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined, within each taxing jurisdiction, that it is more likely than not that the asset will not be realized. The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision (Benefit) for Income Taxes. Penalties, if incurred, are recognized as a component of Selling, General and Administrative Expenses (“SG&A”). The Company and its subsidiaries file a consolidated U.S. federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates. Derivative Financial Instruments The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value . Changes in the fair value of derivative instruments are recorded in earnings unless hedge accounting criteria are met. The Company designated its interest rate swap (refer to Note 8 “Debt”) and foreign currency contracts (refer to Note 13 “Commitments and Contingencies”) entered into as cash flow hedges. The effective portion of the changes in fair value of these cash flow hedges is recorded each period, net of tax, in Accumulated Other Comprehensive Income until the related hedged transaction occurs. Any ineffective portion of the changes in fair value of these cash flow hedges is recorded in earnings. In the event the hedged cash flow for forecasted transactions does not occur, or it becomes probable that they will not occur, the Company reclassifies the amount of any gain or loss on the related cash flow hedge to income (expense) at that time. Cash flows related to these derivative financial instruments are included in cash flows from operating activities. The cash flows from the termination of interest rate swap agreements are reported as operating activities in the Consolidated Statements of Cash Flows. Revenue Recognition The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The Company has elected to adopt the practical expedient provided in ASC 340-40-25-4 and recognize the incremental costs of obtaining a contract, which are primarily sales commissions, as expense when incurred because the amortization period is less than one year. The Company evaluates the pattern of revenue recognition as a performance obligation is satisfied and the customer has obtained control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits of the product. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Accordingly, the majority of the Company’s revenues are recognized at the point of shipment. In instances where title and risk of ownership do not transfer to the customer until the products have reached the customer’s location, revenue is recognized at that point in time. Revenue is recognized net of sales tax, value-added taxes and other taxes. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Performance Obligations The Company considers each shipment of an individual product included on a purchase order to be a separate performance obligation, as each shipment is separately identifiable and the customer can benefit from each individual product separately from the other products included on the purchase order. Accordingly, a contract can have one or more performance obligations to manufacture products. Standard payment terms range from 30 to 90 days and can include a discount for early payment. The Company does not offer its customers a right of return. Rather, the Company warrants that each unit received by the customer will meet the agreed upon technical and quality specifications and requirements. Only when the delivered units do not meet these requirements can the customer return the non-compliant units as a corrective action under the warranty. The remedy offered to the customer is repair of the returned units or replacement if repair is not viable. Accordingly, the Company records a warranty reserve and any warranty activities are not considered to be a separate performance obligation. Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivable and less frequently, unearned revenue. Accounts receivable are recorded when the right to consideration becomes unconditional. Unearned revenue is recorded when customers pay or are billed in advance of the Company’s satisfaction of performance obligations. Contract liabilities were $2.3 million and $2.2 million as of December 28, 2018 and December 29, 2017, respectively, and are classified as Accrued Expenses on the Consolidated Balance Sheets. During the year ended December 28, 2018, the Company recognized $1.9 million of revenue that was included in the contract liability balance as of December 29, 2017. The Company does not have any contract assets. Transaction Price Generally, the transaction price of the Company’s contracts consists of a unit price for each individual product included in the contract, which can be fixed or variable based on the number of units ordered. In some instances, the transaction price also includes a rebate for meeting certain volume-based targets over a specified period of time. The transaction price of a contract is determined based on the unit price and the number of units ordered, reduced by the rebate expected to be earned on those units. Rebates are estimated based on the expected achievement of the volume-based target using the most likely amount method and updated quarterly. Any adjustments to these estimates are recognized under the cumulative catch-up method, such that impact of the adjustment is recognized in the period in which it is identified. Volume discounts and rebates and other pricing concessions earned by customers are offset against their receivable balances. The transaction price is allocated to each performance obligation on a relative standalone selling price basis. As the majority of products sold to customers are manufactured to meet the specific requirements and technical specifications of that customer, the products are considered unique to that customer and the unit price stated in the contract is considered the standalone selling price. The Company has elected to adopt the practical expedient provided in ASC 606-10-50-14 and not disclose the aggregate amount of the transaction price allocated to unsatisfied performance obligations and an expectation of when those amounts are expected to be recognized as revenue because the majority of contracts have an original expected duration of one year or less. Contract Modifications Contract modifications, which can include a change in either or both scope and price, most often occur related to contracts that are governed by a long-term arrangement. Contract modifications typically relate to the same products already governed by the long-term arrangement, and therefore, are accounted for as part of the existing contract. If a contract modification is for additional products, it is accounted for as a separate contract. Environmental Costs Environmental expenditures that relate to an existing condition caused by past operations and that do not provide future benefits are expensed as incurred. Liabilities are recorded when environmental assessments are made, the requirement for remedial efforts is probable and the amount of the liability can be reasonably estimated. Liabilities are recorded generally no later than the completion of feasibility studies. The Company has an ongoing monitoring and identification process to assess how the activities, with respect to known exposures, are progressing against the recorded liabilities, as well as to identify other potential remediation sites that are presently unknown. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Restructuring Expenses The Company continually evaluates alternatives to align the business with the changing needs of its customers and to lower operating costs. This includes the realignment of its existing manufacturing capacity, facility closures, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in employees receiving voluntary or involuntary employee termination benefits, which may be pursuant to contractual agreements. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. All other exit costs are expensed as incurred. Refer to Note 11 “Other Operating Expenses” for additional information. Product Warranties The Company allows customers to return defective or damaged products for credit, replacement, or repair. The Company warrants that its products will meet customer specifications and will be free from defects in materials and workmanship . The Company accrues its estimated exposure to warranty claims, through Cost of Sales, based upon recent historical experience and other specific information as it becomes available. Note 13 “Commitments and Contingencies” contains additional information on the Company’s product warranties. Research, Development and Engineering Costs (“RD&E”) RD&E costs are expensed as incurred. The primary costs are salary and benefits for personnel, material costs used in development projects and subcontracting costs. Stock-Based Compensation The Company recognizes stock-based compensation exp

Divestiture and Acquisition

Divestiture and Acquisition	12 Months Ended
	Dec. 28, 2018
Divestiture and Acquisition [Abstract]
DIVESTITURE AND ACQUISITION	(2.) DISCONTINUED OPERATIONS AND DIVESTITURES Discontinued Operations and Divestiture of AS&O Product Line On May 3, 2018, the Company entered into a definitive agreement to sell its AS&O Product Line to Viant, and on July 2, 2018, completed the sale, collecting cash proceeds of approximately $581 million , which is net of transaction costs and adjustments set forth in the definitive purchase agreement. In connection with the sale, the parties executed a transition services agreement whereby the Company will provide certain corporate services (including accounting, payroll, and information technology services) to Viant for a period of up to one year from the date of the closing to facilitate an orderly transfer of business operations. Viant will pay Integer for these services, with such payments varying in amount and length of time as specified in the transition services agreement. The Company recognized $3.6 million of income under the transition services agreement for the performance of services during 2018, of which $0.2 million is within Cost of Sales and $3.4 million is within Selling, General and Administrative expenses in the Consolidated Statement of Operations for the year ended December 28, 2018. In addition, the parties executed long-term supply agreements under which the Company and Viant have agreed to supply the other with certain products at prices specified in the agreements for a term of three years. In connection with the closing of the transaction, the Company recognized a pre-tax gain on sale of discontinued operations of $195.0 million . The Company is in the process of finalizing the net working capital adjustment with Viant as provided for in the definitive purchase agreement. The final net working capital adjustment, as determined through the established process outlined in the definitive purchase agreement, may be different from the Company’s estimates. The impact of any changes in the net working capital adjustment will be recorded as an adjustment to the gain on sale from discontinued operations in the period such change occurs. Additionally, the income taxes associated with the gain will be impacted by the final allocation of the sales price, which must be agreed to with Viant as required in the definitive purchase agreement and may be materially different from the Company’s estimates. The impact of any changes in estimated income taxes will be recorded as an adjustment to discontinued operations in the period such change in estimate occurs. As the AS&O Product Line was a portion of the Medical goodwill reporting unit, and management determined it met the definition of a business, goodwill was allocated to the AS&O Product Line on a relative fair value basis. The fair value of the AS&O Product Line assets was based primarily on the purchase price of $600 million prior to closing adjustments. The carrying amounts of the AS&O Product Line assets and liabilities that were classified as assets and liabilities of discontinued operations held for sale were as follows (in thousands): December 29, Cash and cash equivalents $ 6,755 Accounts receivable, net of allowance for doubtful accounts of $0.3 million 47,611 Inventories 50,796 Prepaid expenses and other current assets 1,584 Current assets of discontinued operations held for sale 106,746 Property, plant and equipment, net 135,195 Goodwill 150,368 Other intangible assets, net 57,520 Other noncurrent assets 1,551 Noncurrent assets of discontinued operations held for sale 344,634 Total assets 451,380 Accounts payable and other current liabilities held for sale 47,703 Deferred taxes and other long-term liabilities held for sale 14,966 Total liabilities 62,669 Net assets $ 388,711 (2.) DISCONTINUED OPERATIONS AND DIVESTITURES (Continued) Income (loss) from discontinued operations, net of taxes, for fiscal years 2018, 2017 and 2016 were as follows (in thousands): 2018 2017 2016 Sales $ 178,020 $ 325,841 $ 311,276 Cost of sales 148,357 286,300 270,656 Gross profit 29,663 39,541 40,620 Selling, general and administrative expenses 8,905 18,500 16,847 Research, development and engineering costs 2,352 6,397 7,102 Other operating expenses 1,805 854 1,324 Interest expense 22,833 42,488 42,939 Gain on sale of discontinued operations (194,965 ) — — Other (income) loss, net 420 (1,266 ) (612 ) Income (loss) from discontinued operations before taxes 188,313 (27,432 ) (26,980 ) Provision (benefit) for income taxes 67,382 (7,024 ) (8,063 ) Income (loss) from discontinued operations $ 120,931 $ (20,408 ) $ (18,917 ) Interest expense included in discontinued operations reflects an estimate of interest expense related to the debt that was required to be repaid with the proceeds from the sale of the AS&O Product Line. Cash flow information from discontinued operations for fiscal years 2018 , 2017 and 2016 was as follows (in thousands): 2018 2017 2016 Cash used in operating activities $ (12,498 ) $ 3,167 $ 3,596 Cash provided by (used in) investing activities 577,833 (16,771 ) (17,367 ) Depreciation and amortization $ 7,450 $ 21,613 $ 17,656 Capital expenditures 3,610 16,844 17,656 Spin-off of Nuvectra Corporation On March 14, 2016, Integer completed the spin-off of a portion of its former QiG segment through a tax-free distribution of all of the shares of its former QiG Group, LLC subsidiary to the stockholders of Integer on a pro rata basis. Immediately prior to completion of the Spin-off, QiG Group, LLC was converted into a corporation organized under the laws of Delaware and changed its name to Nuvectra Corporation (“Nuvectra”). On March 14, 2016, each of the Company’s stockholders of record as of the close of business on March 7, 2016 (the “Record Date”) received one share of Nuvectra common stock for every three shares of Integer common stock held as of the Record Date. Upon completion of the Spin-off, Nuvectra became an independent publicly traded company whose common stock is listed on the Nasdaq stock exchange under the symbol “NVTR.” The portion of the former QiG segment spun-off consisted of QiG Group, LLC and its subsidiaries: (i) Algostim, LLC (“Algostim”), (ii) PelviStim LLC (“PelviStim”), and (iii) the Company’s NeuroNexus Technologies (“NeuroNexus”) subsidiary. The operations of Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”) and certain other existing QiG research and development capabilities were retained by the Company and not included as part of the Spin-off. As the Company continues to focus on the design and development of complete medical device systems and components, and more specifically on medical device systems and components in the neuromodulation market, the Spin-off was not considered a strategic shift that had a major effect on the Company’s operations and financial results. Accordingly, the Spin-off is not presented as a discontinued operation in the Company’s Consolidated Financial Statements. The results of Nuvectra are included in the Consolidated Statements of Operations through the date of the Spin-off. In connection with the Spin-off, during the first quarter of 2016, the Company made a cash capital contribution of $75 million to Nuvectra and divested assets of $130.8 million and liabilities of $2.1 million . Nuvectra contributed a pre-tax loss of $5.2 million to the Company’s results of operations for the fiscal year ended December 30, 2016 .

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 28, 2018
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	(3.) SUPPLEMENTAL CASH FLOW INFORMATION The following represents supplemental cash flow information, including supplemental information related to discontinued operations, for fiscal years 2018 , 2017 and 2016 (in thousands): 2018 2017 2016 Noncash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 2,303 $ 3,474 $ 3,499 Cash paid (refunded) during the year for: Interest 79,661 93,839 106,475 Income taxes 23,155 (8,185 ) 7,263 Cash and cash equivalents, end of period, are comprised of: Cash and cash equivalents $ 25,569 $ 37,341 Cash included in current assets of discontinued operations held for sale — 6,755 Total cash and cash equivalents, end of period $ 25,569 $ 44,096

Inventories

Inventories	12 Months Ended
	Dec. 28, 2018
Inventory Disclosure [Abstract]
INVENTORIES	(4.) INVENTORIES Inventories are comprised of the following (in thousands): December 28, December 29, Raw materials $ 80,213 $ 85,050 Work-in-process 75,711 63,620 Finished goods 34,152 28,068 Total $ 190,076 $ 176,738

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 28, 2018
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	(5.) PROPERTY, PLANT AND EQUIPMENT, NET PP&E is comprised of the following (in thousands): December 28, 2018 December 29, Manufacturing machinery and equipment $ 261,912 $ 249,233 Buildings and building improvements 95,886 97,346 Information technology hardware and software 60,901 54,302 Leasehold improvements 61,418 58,918 Furniture and fixtures 15,082 15,068 Land and land improvements 11,544 13,146 Construction work in process 23,886 19,758 Other 1,048 829 531,677 508,600 Accumulated depreciation (300,408 ) (273,420 ) Total $ 231,269 $ 235,180 Depreciation expense for PP&E was as follows for fiscal years 2018 , 2017 and 2016 (in thousands): 2018 2017 2016 Depreciation expense $ 40,078 $ 38,077 $ 37,398

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net	12 Months Ended
	Dec. 28, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, Net	(6. ) GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill The change in the carrying amount of goodwill by reportable segment during fiscal year 2018 was as follows (in thousands): Medical Non-Medical Total December 29, 2017 $ 822,870 $ 17,000 $ 839,870 Foreign currency translation (7,532 ) — (7,532 ) December 28, 2018 $ 815,338 $ 17,000 $ 832,338 As of December 28, 2018 , no accumulated impairment loss has been recognized for the goodwill allocated to the Company’s Medical or Non-Medical segments. Intangible Assets Intangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Net Carrying Amount December 28, 2018 Definite-lived: Purchased technology and patents $ 241,726 $ (125,540 ) $ 116,186 Customer lists 710,406 (104,556 ) 605,850 Other 3,503 (3,489 ) 14 Total amortizing intangible assets $ 955,635 $ (233,585 ) $ 722,050 Indefinite-lived: Trademarks and tradenames $ 90,288 December 29, 2017 Definite-lived: Purchased technology and patents $ 243,679 $ (111,185 ) $ 132,494 Customer lists 718,649 (78,621 ) 640,028 Other 4,660 (4,597 ) 63 Total amortizing intangible assets $ 966,988 $ (194,403 ) $ 772,585 Indefinite-lived: Trademarks and tradenames $ 90,288 Aggregate intangible asset amortization expense is comprised of the following for fiscal years 2018 , 2017 and 2016 (in thousands): 2018 2017 2016 Cost of sales $ 14,134 $ 15,183 $ 15,368 SG&A 26,658 24,840 19,590 RD&E 154 545 512 Other Operating Expenses (“OOE”) 514 2,538 — Total intangible asset amortization expense $ 41,460 $ 43,106 $ 35,470 Estimated future intangible asset amortization expense based upon the carrying value as of December 28, 2018 is as follows (in thousands): 2019 2020 2021 2022 2023 After 2023 Amortization Expense $ 40,200 $ 40,511 $ 39,658 $ 38,623 $ 36,779 $ 526,279

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 28, 2018
Accounts Payable and Accrued Liabilities [Abstract]
ACCRUED EXPENSES	(7. ) ACCRUED EXPENSES Accrued expenses are comprised of the following (in thousands): December 28, 2018 December 29, Salaries and benefits $ 21,830 $ 25,103 Profit sharing and bonuses 22,912 13,625 Product warranties 2,600 2,820 Deferred revenue 2,482 1,610 Accrued interest 1,944 8,523 Other 8,722 8,695 Total $ 60,490 $ 60,376

Debt

Debt	12 Months Ended
	Dec. 28, 2018
Debt Disclosure [Abstract]
DEBT	(8.) DEBT Long-term debt is comprised of the following (in thousands): December 28, 2018 December 29, Senior secured term loan A $ 304,687 $ 335,157 Senior secured term loan B 632,286 873,286 9.125% senior notes due 2023 — 360,000 Revolving line of credit 5,000 74,000 Unamortized discount on term loan B and debt issuance costs (16,466 ) (33,278 ) Total debt 925,507 1,609,165 Current portion of long-term debt (37,500 ) (30,469 ) Total long-term debt $ 888,007 $ 1,578,696 Senior Secured Credit Facilities The Company has senior secured credit facilities (the “Senior Secured Credit Facilities”) consisting of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), (ii) a $305 million term loan A facility (the “TLA Facility”), and (iii) a $632 million term loan B facility (the “TLB Facility”). The TLA Facility and TLB Facility are collectively referred to as the “Term Loan Facilities.” The TLB Facility was issued at a 1% discount. On June 8, 2018, the Company amended the Senior Secured Credit Facilities to permit the sale of the AS&O Product Line. As required by the amended terms of the Company’s Senior Secured Credit Facilities, the Company paid down indebtedness as a result of the disposition of the AS&O Product Line. On July 10, 2018, the Company completed the redemption in full of its 9.125% senior notes due on November 1, 2023 (the “Senior Notes”) at a redemption price of 100% of the principal amount of the Senior Notes plus the applicable “make-whole” premium of $31.3 million and accrued and unpaid interest through the redemption date. Upon completion of the redemption of the Senior Notes, the indenture governing the Senior Notes was satisfied and discharged. The Company utilized the remaining net proceeds to pay down an additional $188 million outstanding under the Senior Secured Credit Facilities, consisting of $114 million on the TLB Facility and $74 million on the Revolving Credit Facility. Revolving Credit Facility The Revolving Credit Facility matures on October 27, 2020 . The Revolving Credit Facility includes a $15 million sublimit for swingline loans and a $25 million sublimit for standby letters of credit. The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.175% and 0.25% , depending on the Company’s Total Net Leverage Ratio (as defined in the Senior Secured Credit Facilities agreement). Interest rates on the Revolving Credit Facility, as well as the TLA Facility, are at the Company’s option, either at: (i) the prime rate plus the applicable margin, which will range between 0.75% and 2.25% , based on the Company’s Total Net Leverage Ratio, or (ii) the applicable LIBOR rate plus the applicable margin, which will range between 1.75% and 3.25% , based on the Company’s Total Net Leverage Ratio. (8.) DEBT (Continued) As of December 28, 2018 , the Company had $5 million of outstanding borrowings on the Revolving Credit Facility and an available borrowing capacity of $188.2 million after giving effect to $6.8 million of outstanding standby letters of credit. As of December 28, 2018 , the weighted average interest rate on outstanding borrowings under the Revolving Credit Facility was 5.01% . Subject to certain conditions, commitments under the Revolving Credit Facility may be increased through an incremental revolving facility so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25 :1.00. Term Loan Facilities The TLA Facility and TLB Facility mature on October 27, 2021 and October 27, 2022 , respectively. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the prime rate plus 2.00% or (ii) the applicable LIBOR rate plus 3.00% , with LIBOR subject to a 1.00% floor. As of December 28, 2018 , the interest rates on the TLA Facility and TLB Facility were 5.01% and 5.39% , respectively. Subject to certain conditions, one or more incremental term loan facilities may be added to the Term Loan Facilities so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25 :1.00. Covenants The Revolving Credit Facility and the TLA Facility contain covenants requiring (A) a maximum total net leverage ratio of 5.50 :1.0, subject to step downs beginning in the first quarter of 2019 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of not less than 2.75 :1.0, subject to step ups beginning in the first quarter of 2019. As of December 28, 2018 , the Company was in compliance with these financial covenants. The TLB Facility does not contain any financial maintenance covenants. The Senior Secured Credit Facilities also contain negative covenants that restrict the Company’s ability to (i) incur additional indebtedness; (ii) create certain liens; (iii) consolidate or merge; (iv) sell assets, including capital stock of the Company’s subsidiaries; (v) engage in transactions with the Company’s affiliates; (vi) create restrictions on the payment of dividends or other amounts from the Company’s restricted subsidiaries; (vii) pay dividends on capital stock or redeem, repurchase or retire capital stock; (viii) pay, prepay, repurchase or retire certain subordinated indebtedness; (ix) make investments, loans, advances and acquisitions; (x) make certain amendments or modifications to the organizational documents of the Company or its subsidiaries or the documentation governing other senior indebtedness of the Company; and (xi) change the Company’s type of business. These negative covenants are subject to a number of limitations and exceptions that are described in the Senior Secured Credit Facilities agreement. As of December 28, 2018 , the Company was in compliance with all negative covenants under the Senior Secured Credit Facilities. The Senior Secured Credit Facilities provide for customary events of default. Upon the occurrence and during the continuance of an event of default, the outstanding advances and all other obligations under the Senior Secured Credit Facilities become immediately due and payable. 9.125% Senior Notes due 2023 On October 27, 2015, the Company completed a private offering of $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 . On July 10, 2018, the Company completed the redemption in full of the Senior Notes at a redemption price of 100% of the principal amount of the Senior Notes plus the applicable “make-whole” premium of $31.3 million and accrued and unpaid interest through the redemption date. The “make-whole” premium is included in Interest Expense in the accompanying Consolidated Statements of Operations. Upon completion of the redemption of the Senior Notes, the indenture governing the Senior Notes was satisfied and discharged. As of December 28, 2018 , the weighted average interest rate on all outstanding borrowings is 5.27% . (8.) DEBT (Continued) Contractual maturities of the Company’s debt facilities for the next five years and thereafter, excluding any discounts or premiums, as of December 28, 2018 are as follows (in thousands): 2019 2020 2021 2022 After 2022 Future minimum principal payments $ 37,500 42,500 229,687 632,286 — Debt Issuance Costs and Discounts The Company incurred debt issuance costs in conjunction with the issuance of the Senior Secured Credit Facilities and the Senior Notes. The change in deferred debt issuance costs related to the Company’s Revolving Credit Facility is as follows (in thousands): December 30, 2016 $ 3,800 Amortization during the period (992 ) December 29, 2017 2,808 Amortization during the period (991 ) December 28, 2018 $ 1,817 The change in unamortized discount and debt issuance costs related to the Term Loan Facilities and Senior Notes is as follows (in thousands): Debt Issuance Costs Unamortized Discount on TLB Facility Total December 30, 2016 $ 32,096 $ 8,741 $ 40,837 Financing costs incurred 2,360 — 2,360 Write-off of debt issuance costs and unamortized discount (1) (2,421 ) (1,104 ) (3,525 ) Amortization during the period (5,146 ) (1,248 ) (6,394 ) December 29, 2017 26,889 6,389 33,278 Write-off of debt issuance costs and unamortized discount (1) (9,757 ) (1,610 ) (11,367 ) Amortization during the period (4,419 ) (1,026 ) (5,445 ) December 28, 2018 $ 12,713 $ 3,753 $ 16,466 __________ (1) The Company redeemed its Senior Notes and prepaid portions of its TLB Facility during 2018 and 2017 and recognized losses from extinguishment of debt of $11.4 million and $3.5 million , respectively, which are included in Interest Expense, Net in the Consolidated Statements of Operations. The loss from extinguishment of debt represents the unamortized debt issuance costs related to the Senior Notes and the portion of the unamortized discount and debt issuance costs related to the portion of the TLB Facility that was prepaid and is included in Interest Expense in the accompanying Consolidated Statements of Operations. (8.) DEBT (Continued) Interest Rate Swap During 2016, the Company entered into a three year $ 200 million interest rate swap to hedge against potential changes in cash flows on the outstanding variable rate debt, which is indexed to the one-month LIBOR rate. The variable rate received on the interest rate swap and the variable rate paid on the variable rate debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same day. The swap is being accounted for as a cash flow hedge. Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of December 28, 2018 is as follows (dollars in thousands): Notional Amount Start Date End Date Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun-17 Jun-20 1.1325 % 2.5063% $ 4,171 Other Assets The estimated fair value of the interest rate swap agreements represents the amount the Company expects to receive (pay) to terminate the contract. No portion of the change in fair value of the Company’s interest rate swaps during 2018 , 2017 , or 2016 were considered ineffective. The amount recorded to Interest Expense related to the Company’s interest rate swaps was a reduction of $1.7 million and $0.5 million during 2018 and 2017, respectively, and an increase of $0.1 million during 2016. The estimated Accumulated Other Comprehensive Income related to the Company’s interest rate swaps that is expected to be reclassified into earnings within the next twelve months is a $2.8 million gain.

Benefit Plans

Benefit Plans	12 Months Ended
	Dec. 28, 2018
Defined Benefit Plan [Abstract]
BENEFIT PLANS	(9. ) BENEFIT PLANS Savings Plan The Company sponsors a defined contribution 401(k) plan (the “Plan”), for its U.S. based employees. The Plan provides for the deferral of employee compensation under Internal Revenue Code §401(k) and a Company match. The Company matches $0. 50 per dollar of participant deferral, up to 6% of the compensation of each participant. Contributions from employees, as well at those matched by the Company, vest immediately. Net costs related to defined contribution plans were $6.8 million in 2018, $6.0 million in 2017 and $4.6 million in 2016. Defined Benefit Plans The Company is required to provide its employees located in Switzerland and Mexico certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico are unfunded and noncontributory. The assets of the Switzerland plan are held at an AA- rated insurance carrier who bears the pension risk and longevity risk, and will be used to cover the pension liability for the remaining retirees of the Swiss plan, as well as the remaining employees at that location. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees. (9. ) BENEFIT PLANS (Continued) The Company’s fiscal year end dates are the measurement dates for its defined benefit plans. Information relating to the funding position of the Company’s defined benefit plans for fiscal years 2018 and 2017 were as follows (in thousands): 2018 2017 Change in projected benefit obligation: Projected benefit obligation at beginning of year $ 2,608 $ 2,285 Service cost 214 200 Interest cost 48 42 Plan participants’ contribution 84 75 Actuarial gain (150 ) (90 ) Benefits (paid) transferred in, net 42 (11 ) Settlements (619 ) — Foreign currency translation (24 ) 107 Projected benefit obligation at end of year 2,203 2,608 Change in fair value of plan assets: Fair value of plan assets at beginning of year 1,358 1,172 Employer contributions 83 56 Plan participants’ contributions 84 75 Actual loss on plan assets (11 ) — Benefits transferred in, net 62 — Settlements (619 ) — Foreign currency translation (11 ) 55 Fair value of plan assets at end of year 946 1,358 Projected benefit obligation in excess of plan assets at end of year $ 1,257 $ 1,250 Defined benefit liability classified as other current liabilities $ 54 $ 32 Defined benefit liability classified as long-term liabilities $ 1,203 $ 1,218 Accumulated benefit obligation at end of year $ 1,809 $ 2,189 Amounts recognized in Accumulated Other Comprehensive Income (Loss) for fiscal years 2018 and 2017 are as follows (in thousands): 2018 2017 Net (gain) loss occurring during the year $ (130 ) $ 74 Amortization of losses (101 ) (45 ) Prior service cost 1 1 Amortization of prior service cost (2 ) (2 ) Pre-tax adjustment (gain) loss (232 ) 28 Tax benefit (70 ) (5 ) Net (gain) loss $ (302 ) $ 23 The amortization of amounts in Accumulated Other Comprehensive Income expected to be recognized as components of net periodic benefit expense during fiscal year 2019 are as follows (in thousands): Amortization of net prior service cost $ 1 Amortization of net loss 5 (9. ) BENEFIT PLANS (Continued) Net pension cost for fiscal years 2018 and 2017 is comprised of the following (in thousands): 2018 2017 2016 Service cost $ 214 $ 200 $ 173 Interest cost 48 42 36 Settlements loss 69 — — Expected return on assets (17 ) (19 ) (18 ) Recognized net actuarial loss 33 44 38 Net pension cost $ 347 $ 267 $ 229 The weighted-average rates used in the actuarial valuations to determine the net pension cost for fiscal years 2018 , 2017 and 2016 were as follows: 2018 2017 2016 Discount rate 3.1% 2.9% 2.3% Salary growth 3.2% 3.1% 2.4% Expected rate of return on assets 1.3% 1.5% 2.0% The weighted-average rates used in the actuarial valuations to determine the projected benefit obligation for fiscal years 2018 , 2017 and 2016 were as follows: 2018 2017 2016 Discount rate 6.0% 3.1% 2.9% Salary growth 4.1% 3.2% 3.1% Expected rate of return on assets 1.4% 1.3% 1.5% The following table provides information by level for the defined benefit plan assets that are measured at fair value as of December 28, 2018 and December 29, 2017 (in thousands). Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 28, 2018 Insurance contract $ 946 $ — $ 946 $ — December 29, 2017 Insurance contract $ 1,358 $ — $ 1,358 $ — The fair value of Level 2 plan assets are obtained from quoted market prices in inactive markets or valuation models with observable market data inputs to estimate fair value. These observable market data inputs include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and reference data. Refer to Note 1 “Summary of Significant Accounting Policies” for discussion of the fair value measurement terms of Levels 1, 2, and 3. Estimated benefit payments over for the next ten years as of December 28, 2018 are as follows (in thousands): 2019 2020 2021 2022 2023 2024-2028 Estimated benefit payments $ 104 121 124 134 145 964

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 28, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	(10.) STOCK-BASED COMPENSATION Stock-based Compensation Plans The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors, or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, shares of restricted stock awards, restricted stock units, stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers. The 2009 Stock Incentive Plan (“2009 Plan”), as amended, and 2011 Stock Incentive Plan (“2011 Plan”), as amended, each authorize the issuance of up to 1,350,000 shares of equity incentive awards and the 2016 Stock Incentive Plan (the “2016 Plan”) authorizes the issuance of up to 1,450,000 shares of equity incentive awards. The 2009 Plan limits the amount of restricted stock, restricted stock units and stock bonuses that may be awarded in the aggregate to 200,000 shares of the 1,350,000 shares authorized. Stock options remain outstanding under the 2005 Stock Incentive Plan, but the plan has been frozen to any new award issuances. As of December 28, 2018 , there were 722,766 , 119,866 and 65,190 shares available for future grants under the 2016 Plan, 2011 Plan and 2009 Plan, respectively. Due to plan sub-limits, of the shares available for grant, 7,488 shares may be awarded under the 2009 Plan in the form of restricted stock, restricted stock units or stock bonuses. The Company recognized a net tax benefit from the exercise of stock options and vesting of restricted stock and restricted stock units of $3.8 million , $1.9 million and $2.3 million for 2018 , 2017 and 2016 , respectively. Beginning in 2017, this amount was recorded as a component of income tax expense. In 2016, these amounts were recorded as increases in additional paid-in capital on the Consolidated Balance Sheets and as cash from financing activities on the Consolidated Statements of Cash Flows. Stock-based Compensation Expense The components and classification of stock-based compensation expense for fiscal years 2018 , 2017 and 2016 were as follows (in thousands): 2018 2017 2016 Stock options $ 873 $ 1,633 $ 2,455 RSAs and RSUs (time-based) 6,024 4,952 1,764 PRSUs 3,159 6,867 3,887 Stock-based compensation expense - continuing operations 10,056 $ 13,452 $ 8,106 Discontinued operations 414 1,228 302 Total stock-based compensation expense $ 10,470 $ 14,680 $ 8,408 Cost of sales $ 849 $ 748 $ 208 SG&A 9,090 9,893 6,086 RD&E 112 642 337 OOE 5 2,169 1,475 Discontinued operations 414 1,228 302 Total stock-based compensation expense $ 10,470 $ 14,680 $ 8,408 During the first quarter of 2017, the Company recorded $2.2 million of accelerated stock-based compensation expense in connection with the transition of its former Chief Executive Officer per the terms of his contract, which was classified as OOE. During the first quarter of 2016, the Company recorded $0.5 million of accelerated stock-based compensation expense in connection with the Spin-off, which was classified as OOE. (10.) STOCK-BASED COMPENSATION (Continued) Stock Options The following table includes the weighted average grant date fair value of stock options granted to employees during fiscal years 2018 , 2017 and 2016 and the related weighted average assumptions used in the Black-Scholes model: 2018 2017 2016 Weighted average fair value of options granted $ 14.89 $ 12.86 $ 8.52 Assumptions: Expected term (in years) 4.0 4.5 4.7 Risk-free interest rate 2.21 % 1.77 % 1.49 % Expected volatility 39 % 37 % 27 % Expected dividend yield 0 % 0 % 0 % The following table summarizes stock option activity during the fiscal year ended December 28, 2018 : Number of Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in millions) Outstanding at December 29, 2017 931,353 $ 30.89 Granted 28,447 45.13 Exercised (413,317 ) 30.02 Forfeited or expired (23,700 ) 41.28 Outstanding at December 28, 2018 522,783 $ 31.88 5.8 $ 23.1 Vested and expected to vest at December 28, 2018 522,783 $ 31.88 5.8 $ 23.1 Exercisable at December 28, 2018 488,468 $ 31.37 5.6 $ 21.8 Intrinsic value is calculated for in-the-money options (exercise price less than market price) as the difference between the market price of the Company’s common shares as of December 28, 2018 ( $76.03 ) and the weighted average exercise price of the underlying stock options, multiplied by the number of options outstanding and/or exercisable. As of December 28, 2018 , $0.5 million of unrecognized compensation cost related to non-vested stock options is expected to be recognized over a weighted-average period of 1.2 years. Shares are distributed from the Company’s authorized but unissued reserve upon the exercise of stock options. The following table provides certain information relating to the exercise of stock options during fiscal years 2018 , 2017 and 2016 (in thousands): 2018 2017 2016 Intrinsic value $ 17,722 $ 13,928 $ 690 Cash received 12,409 19,324 2,821 (10.) STOCK-BASED COMPENSATION (Continued) Restricted Stock Awards and Restricted Stock Units The following table summarizes time-vested RSA and RSU activity during the fiscal year ended December 28, 2018 : Time-Vested Restricted Stock Units and Awards Weighted Average Grant Date Fair Value Nonvested at December 29, 2017 163,431 $ 35.96 Granted 167,514 52.14 Vested (134,423 ) 38.88 Forfeited (54,286 ) 42.44 Nonvested at December 28, 2018 142,236 $ 49.78 As of December 28, 2018 , there was $5.8 million of total unrecognized compensation cost related to time-based RSAs and RSUs, which is expected to be recognized over a weighted-average period of approximately 2.3 years. The fair value of RSA and RSU shares vested in 2018 , 2017 and 2016 was $9.7 million , $6.4 million and $1.3 million , respectively. The weighted average grant date fair value of RSAs and RSUs granted during fiscal years 2018 , 2017 and 2016 was $52.14 , $34.18 and $47.95 , respectively. Performance-Based Shares The following table summarizes the maximum number of PRSUs which could be earned and related activity during the fiscal year ended December 28, 2018 : Performance- Vested Restricted Stock Units and Awards Weighted Average Grant Date Fair Value Nonvested at December 29, 2017 469,889 $ 32.37 Granted 159,669 45.37 Vested (161,674 ) 35.28 Forfeited (180,750 ) 35.24 Nonvested at December 28, 2018 287,134 $ 36.15 For the Company's PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of financial performance or market-based conditions. The financial performance condition is based on the Company's sales targets. The market conditions are based on the Company’s achievement of a relative total shareholder return performance requirement, on a percentile basis, compared to a defined group of peer companies over two and three year performance periods. Compensation expense for the PRSUs is initially estimated based on target performance and adjusted as appropriate throughout the performance period. At December 28, 2018 , there was $3.3 million of total unrecognized compensation cost related to unvested PRSUs, which is expected to be recognized over a weighted-average period of approximately 1.9 years . The fair value of PRSU shares vested in 2018 and 2016 was $9.1 million and $10.5 million , respectively. There were no PRSU shares vested in 2017. The weighted average grant date fair value of PRSUs granted during fiscal years 2018 , 2017 and 2016 was $45.37 , $31.62 and $30.83 , respectively. The grant-date fair value of the market-based portion of the PRSUs granted during fiscal year 2018 was determined using the Monte Carlo simulation model on the date of grant, assuming the following (i) expected term of 2.92 years , (ii) risk free interest rate of 2.28% , (iii) expected dividend yield of 0.0% and (iv) expected stock price volatility over the expected term of the award of 40% .

Other Operating Expenses

Other Operating Expenses	12 Months Ended
	Dec. 28, 2018
Other Income and Expenses [Abstract]
OTHER OPERATING EXPENSES	11.) OTHER OPERATING EXPENSES OOE for fiscal years 2018 , 2017 and 2016 is comprised of the following (in thousands): 2018 2017 2016 Strategic reorganization and alignment $ 10,624 $ 5,891 $ — Manufacturing alignment to support growth 3,089 — — Consolidation and optimization initiatives 844 12,803 25,510 Acquisition and integration costs — 10,870 28,112 Asset dispositions, severance and other 1,508 6,874 6,791 Other operating expenses $ 16,065 $ 36,438 $ 60,413 Strategic reorganization and alignment During the fourth quarter of 2017, the Company began to take steps to better align its resources in order to enhance the profitability of its portfolio of products. This includes improving its business processes and redirecting investments away from projects where the market does not justify the investment, as well as aligning resources with market conditions and the Company’s future strategic direction. The Company estimates that it will incur aggregate pre-tax charges in connection with the strategic reorganization and alignment plan of between approximately $28 million to $30 million , of which an estimated $16 million to $20 million are expected to result in cash outlays. During 2018, the Company incurred charges relating to this initiative which primarily included severance and personnel related costs for terminated employees and fees for professional services. These expenses were primarily recorded within the Medical segment. As of December 28, 2018, total expense incurred for this initiative since inception, including amounts reported in discontinued operations, was $16.5 million . These actions are expected to be substantially completed by the end of 2019. Manufacturing alignment to support growth In 2017, the Company initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of the Company's facilities. The Company estimates that it will incur aggregate pre-tax restructuring related charges in connection with the realignment plan of between approximately $9 million to $11 million , the majority of which are expected to be cash expenditures, and capital expenditures of between approximately $4 million to $6 million . Costs related to the Company’s manufacturing alignment to support growth initiative were primarily recorded within the Medical segment. As of December 28, 2018, total expense incurred for this initiative since inception was $3.4 million . These actions are expected to be substantially completed by the end of 2019. Consolidation and optimization initiatives In 2014, the Company initiated plans to transfer certain manufacturing functions performed at its facility in Beaverton, OR to a new facility in Tijuana, Mexico. Additionally, during 2016, the Company announced it would be closing its facility in Clarence, NY after transferring the machined component product lines manufactured in that facility to other Integer locations in the U.S. Costs related to the Company’s consolidation and optimization initiatives were primarily recorded within the Medical segment. The Company does not expect to incur any additional material costs associated with these activities as these activities are substantially complete. The following table summarizes the change in accrued liabilities related to the initiatives described above (in thousands): Severance and Retention Accelerated Depreciation/ Asset Write-offs Other Total December 29, 2017 $ 1,308 $ — $ — $ 1,308 Restructuring charges 3,812 514 10,231 14,557 Write-offs — (514 ) — (514 ) Cash payments (3,452 ) — (10,029 ) (13,481 ) December 28, 2018 $ 1,668 $ — $ 202 $ 1,870 (11.) OTHER OPERATING EXPENSES (Continued) Acquisition and Integration Expenses The Company did not incur any additional costs associated with these activities during the year ended December 28, 2018 . Acquisition and integration costs are predominantly related to the acquisition of LRM and primarily include professional, consulting, severance, retention, relocation, and travel costs. Integration costs primarily include professional, consulting, severance, retention, relocation, and travel costs. The $0.4 million of acquisition and integration costs accrued as of December 29, 2017 were paid during the first quarter of 2018. These projects were completed as of December 29, 2017. Asset Dispositions, Severance and Other During 2018 , 2017 and 2016 , the Company recorded losses in connection with various asset disposals and/or write-downs. The 2017 amount also includes approximately $5.3 million in expense related to the Company’s leadership transitions, which were recorded within the corporate unallocated segment. In addition, the 2016 amount includes the legal and professional costs incurred in connection with the Spin-off of $4.4 million . Expenses related to the Spin-off were primarily recorded within the corporate unallocated and the Medical segment.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 28, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	(12.) INCOME TAXES On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017. Under GAAP, the effect of a change in tax laws or rates is to be recognized in income from continuing operations in the period that includes the enactment date. As such, the Company recognized an estimate of the impact of the Tax Reform Act in the year ended December 29, 2017. The Company had an estimated $147.5 million of undistributed foreign earnings and profit subject to the deemed mandatory repatriation as of December 29, 2017 and recognized a provisional $14.7 million in 2017 for the one-time transition tax. The Company has sufficient U.S. net operating losses to offset cash tax liabilities associated with the repatriation tax. In addition, as a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Reform Act, the Company revalued its ending net deferred tax liabilities at December 29, 2017 and recognized a $56.5 million tax benefit in the Company’s Consolidated Statement of Operations for the year ended December 29, 2017. On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB”) No. 118 to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Reform Act. The Company recognized the tax impact of the revaluation of deferred tax assets and liabilities and the provisional tax impact related to deemed repatriated earnings and included these amounts in its consolidated financial statements for the year ended December 29, 2017. Based on additional analysis conducted, the Company updated the provisional amount of the one-time transition tax to $18.9 million , representing an increase of $4.2 million over the $14.7 million amount recorded as of December 29, 2017. As stated above, the Company has sufficient U.S. net operating losses to offset cash tax liabilities associated with the repatriation tax. In part, due to the utilization of additional net operating losses to offset the additional transition tax, the Company adjusted its revaluation of the adjusted ending net deferred tax liabilities as of December 29, 2017, resulting in a recognized tax benefit of $60.7 million , representing an increase of $4.2 million to the originally recorded $56.5 million tax benefit recorded in the Company’s Consolidated Statement of Operations for the year ended December 29, 2017. In 2018, the Company completed its determination of the accounting implications of the Tax Reform Act. The impact of these adjustments has been reflected in the Company’s financial results for the year ended December 28, 2018 and its timely filed 2017 U.S. corporate income tax return. Further, the Company has adopted the approach of recording the consequences of the new Global Intangible Low-Taxed Income (“GILTI”) provision of the Tax Reform Act as a period cost when incurred. (12.) INCOME TAXES (Continued) Income from continuing operations before provision (benefit) for income taxes for fiscal years 2018 , 2017 and 2016 consisted of the following (in thousands): 2018 2017 2016 U.S. $ (4,273 ) $ 306 $ (12,547 ) International 65,389 48,953 40,712 Total income before income taxes from continuing operations $ 61,116 $ 49,259 $ 28,165 The provision (benefit) for income taxes from continuing operations for fiscal years 2018 , 2017 and 2016 was comprised of the following from continuing operations (in thousands): 2018 2017 2016 Current: Federal $ 80 $ (1,558 ) $ (8,327 ) State 166 (29 ) 149 International 9,490 8,539 7,230 9,736 6,952 (948 ) Deferred: Federal 6,610 (45,114 ) 5,457 State 103 (295 ) 527 International (2,366 ) 629 (1,749 ) 4,347 (44,780 ) 4,235 Total provision (benefit) for income taxes $ 14,083 $ (37,828 ) $ 3,287 The provision (benefit) for income taxes from continuing operations differs from the U.S. statutory rate for fiscal years 2018 , 2017 and 2016 due to the following: 2018 2017 2016 Statutory rate $ 12,834 21.0 % $ 17,240 35.0 % $ 9,858 35.0 % Federal tax credits (1,700 ) (2.8 ) (1,674 ) (3.4 ) (1,570 ) (5.6 ) Foreign rate differential (6,040 ) (9.9 ) (12,934 ) (26.3 ) (9,665 ) (34.3 ) Uncertain tax positions 147 0.2 34 0.1 219 0.8 State taxes, net of federal benefit 975 1.6 (543 ) (1.1 ) (311 ) (1.1 ) U.S. tax on foreign earnings 10,473 17.1 1,471 3.0 1,508 5.4 Valuation allowance (567 ) (0.9 ) 1,030 2.1 1,273 4.5 Tax Reform Act 11 — (39,394 ) (80.0 ) — — Change in tax rates — — — — (270 ) (1.0 ) Non-deductible transaction costs — — — — 1,012 3.6 Change in tax law (Internal Revenue Code §987) — — — — 2,630 9.3 Other (2,050 ) (3.3 ) (3,058 ) (6.2 ) (1,397 ) (5.0 ) Effective tax rate $ 14,083 23.0 % $ (37,828 ) (76.8 )% $ 3,287 11.7 % The difference between the Company’s effective tax rate and the U.S. federal statutory income tax rate in the current year is primarily attributable to the components of Tax Reform Act as well as the impact of the Company’s earnings realized in foreign jurisdictions with statutory rates that are different than the federal statutory rate. The Company’s foreign earnings are primarily derived from Switzerland, Mexico, Uruguay, and Ireland. In addition, the Company currently has a tax holiday in Malaysia through April 2023 provided certain conditions are met. Beginning in 2018, certain earnings realized in foreign jurisdictions are subject to U.S. tax in accordance with the Tax Reform Act. (12.) INCOME TAXES (Continued) Difference Attributable to Foreign Investment: Certain foreign subsidiary earnings are subject to U.S. taxation under the Tax Reform Act. The Company intends to permanently reinvest substantially all of our foreign subsidiary earnings, as well as our capital in our foreign subsidiaries, with the exception of distributions made out of current year earnings and profits (E&P) and E&P previously taxed as of and for the year ended December 29, 2017, including E&P subject to the toll charge under the Tax Reform Act. The Company accrues for withholding taxes on distributions in the year that distributions are made. The net deferred tax liability, including discontinued operations at December 29, 2017, consists of the following (in thousands): December 28, December 29, Net operating loss carryforwards $ 18,088 $ 107,005 Tax credit carryforwards 24,593 28,215 Inventories 3,408 4,956 Accrued expenses 39 3,815 Stock-based compensation 2,340 5,531 Gross deferred tax assets 48,468 149,522 Less valuation allowance (34,339 ) (36,480 ) Net deferred tax assets 14,129 113,042 Property, plant and equipment (9,445 ) (27,547 ) Intangible assets (198,648 ) (219,576 ) Convertible subordinated notes — (806 ) Other (6,009 ) (6,325 ) Gross deferred tax liabilities (214,102 ) (254,254 ) Net deferred tax liability $ (199,973 ) $ (141,212 ) Presented as follows: Noncurrent deferred tax asset $ 3,937 $ 4,152 Noncurrent deferred tax liability (203,910 ) (145,364 ) Net deferred tax liability $ (199,973 ) $ (141,212 ) The components of the net deferred tax liability, by balance sheet account, were as follows: December 28, December 29, Deferred income tax asset $ 3,937 $ 3,451 Noncurrent assets of discontinued operations held for sale — 701 Deferred income tax liabilities (203,910 ) (140,964 ) Noncurrent liabilities of discontinued operations held for sale — (4,400 ) Net deferred tax liability $ (199,973 ) $ (141,212 ) As of December 28, 2018 , the Company has the following carryforwards available: Jurisdiction Tax Attribute Amount (in millions) Begin to Expire U.S. Federal Net operating loss $ 39.1 2034 U.S. State Net operating loss 130.6 2019 International Net operating loss 31.1 2019 U.S. Federal Foreign tax credit 17.0 2019 U.S. Federal and State R&D tax credit 3.6 2019 U.S. State Investment tax credit 6.8 2019 Net operating losses are presented as pre-tax amounts. (12.) INCOME TAXES (Continued) Certain U.S. tax attributes are subject to limitations of Internal Revenue Code §382, which in general provides that utilization is subject to an annual limitation if an ownership change results from transactions increasing the ownership of certain shareholders or public groups in stock of a corporation by more than 50 percentage points over a three-year period. Such an ownership change occurred upon the consummation of the acquisition of LRM in 2015. The Company does not anticipate that these limitations will affect utilization of these carryforwards prior to their expiration. The Company’s federal net operating loss carryforward and certain other federal tax credits reported on its income tax returns included uncertain tax positions taken in prior years. Due to the application of the accounting for uncertain tax positions, the actual tax attributes are larger than the tax amounts for which a deferred tax asset is recognized for financial statement purposes. In assessing the realizability of deferred tax assets, management considers, within each taxing jurisdiction, whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the consideration of the weight of both positive and negative evidence, management has determined that a portion of the deferred tax assets as of December 28, 2018 and December 29, 2017 related to certain foreign tax credits, state investment tax credits, and foreign and state net operating losses will not be realized. The Company files annual income tax returns in the U.S., various state and local jurisdictions, and in various foreign jurisdictions. A number of years may elapse before an uncertain tax position, for which the Company has unrecognized tax benefits, is examined and finally settled. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that its unrecognized tax benefits reflect the most probable outcome. The Company adjusts these unrecognized tax benefits, as well as the related interest, in light of changing facts and circumstances. The resolution of an uncertain tax position, if recognized, would be recorded as an adjustment to the Provision (Benefit) for Income Taxes and the effective tax rate in the period of resolution. Below is a summary of changes to the unrecognized tax benefit for fiscal years 2018 , 2017 and 2016 . The amounts for 2016 and 2017 include discontinued operations. The amounts for 2018 reflect discontinued operations through the date of divestiture of the AS&O product line, which is reflected in the table below as a reduction during 2018 (in thousands): 2018 2017 2016 Balance, beginning of year $ 12,088 $ 10,561 $ 9,271 Additions based upon tax positions related to the current year 300 3,833 1,450 Additions (reductions) related to prior period tax returns (75 ) (14 ) 240 Reductions relating to settlements with tax authorities (98 ) — — Reductions relating to divestiture (6,846 ) — — Reductions as a result of a lapse of applicable statute of limitations — (510 ) — Revaluation due to change in tax rate (Tax Reform Act) — (1,782 ) — Reductions relating to business combinations — — (400 ) Balance, end of year $ 5,369 $ 12,088 $ 10,561 Integer and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The tax years that remain open and subject to tax audits varies depending on the tax jurisdiction. The Internal Revenue Service finalized an audit of the 2012 and 2013 U.S. Federal income tax returns of the Company in the first quarter of 2015. The impact to the income tax expense was not material. The IRS is currently examining the U.S. subsidiaries of the Company for the taxable years 2014 - 2016 and the 2017 - 2018 taxable years remain subject to examination by the IRS. The U.S. subsidiaries of the former LRM are still subject to U.S. federal, state, and local examinations for the taxable years 2006 to 2014. It is reasonably possible that a reduction of approximately $0.9 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of the lapse of the statute of limitations and/or audit settlements. As of December 28, 2018 , approximately $5.3 million of unrecognized tax benefits would favorably impact the effective tax rate (net of federal impact on state issues), if recognized. The Company recognizes interest related to unrecognized tax benefits as a component of Provision (Benefit) for Income Taxes on the Consolidated Statements of Operations. During 2018 , 2017 and 2016 , the recorded amounts for interest and penalties, respectively, were not significant.

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 28, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	(13.) COMMITMENTS AND CONTINGENCIES Litigation In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. Two juries in the U.S. District Court for the District of Delaware have returned verdicts finding that AVX infringed on three of the Company’s patents and awarded the Company $37.5 million in damages. In March 2018, the U.S. District Court for the District of Delaware vacated the original damage award and ordered a retrial on damages. In the January 2019 retrial on damages, the jury awarded the Company $22.2 million in damages. That matter is subject to post-trial proceedings. To date, the Company has recorded no gains in connection with this litigation. The Company is a party to various other legal actions arising in the normal course of business. The Company does not expect that the ultimate resolution of any other pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, will not become material in the future. Environmental Matters In January 2015, Lake Region Medical (“LRM”), which was acquired by the Company in October 2015, was notified by the New Jersey Department of Environmental Protection (“NJDEP”) of NJDEP’s intent to revoke a no further action determination made by NJDEP in favor of LRM in 2002 pertaining to a property on which a subsidiary of LRM operated a manufacturing facility in South Plainfield, New Jersey beginning in 1971. LRM sold the property in 2004 and vacated the facility in 2007. In response to NJDEP’s notice, the Company further investigated the matter and submitted a technical report to NJDEP in August of 2015 that concluded that NJDEP’s notice of intent to revoke was unwarranted. After reviewing the Company’s technical report, NJDEP issued a draft response in May 2016, stating that NJDEP would not revoke the no further action determination at that time, but would require some additional site investigation to support the Company’s conclusion. The Company met with NJDEP representatives to discuss the appropriate scope of the requested additional investigation, and the requested additional investigation is ongoing. The Company does not expect this environmental matter will have a material effect on its consolidated results of operations, financial position or cash flows. License Agreements The Company is a party to various license agreements for technology that is utilized in certain of its products. The most significant of these agreements are the licenses for basic technology used in the production of wet tantalum capacitors, filtered feedthroughs and MRI compatible lead systems. Expenses related to license agreements were $1.6 million , $1.1 million , and $1.0 million , for 2018 , 2017 and 2016 , respectively, and are primarily included in Cost of Sales. Product Warranties The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The change in product warranty liability for fiscal years 2018 and 2017 was comprised of the following (in thousands): 2018 2017 Beginning balance $ 2,820 $ 2,764 Additions to warranty reserve, net of reversals 620 917 Warranty claims settled (840 ) (861 ) Ending balance $ 2,600 $ 2,820 Operating Leases The Company is a party to various operating lease agreements for buildings, machinery, equipment and software. The Company primarily leases buildings, which accounts for the majority of the future lease payments. Lease expense includes the effect of escalation clauses and leasehold improvement incentives which are accounted for ratably over the lease term. Operating lease expense for fiscal years 2018 , 2017 and 2016 was as follows (in thousands): 2018 2017 2016 Operating lease expense $ 10,753 $ 14,320 $ 12,127 (13.) COMMITMENTS AND CONTINGENCIES (Continued) At December 28, 2018 , the Company had the following future minimum lease payments under non-cancelable operating leases (in thousands): 2019 2020 2021 2022 2023 After 2023 Future minimum lease payments $ 8,562 7,290 7,348 5,269 5,112 14,589 Self-Insurance Liabilities As of December 28, 2018 , and at various times in the past, the Company self-funded its workers' compensation and employee medical and dental expenses. The Company has established reserves to cover these self-insured liabilities and also maintains stop-loss insurance to limit its exposures under these programs. Claims reserves represent accruals for the estimated uninsured portion of reported claims, including adverse development of reported claims, as well as estimates of incurred but not reported claims. Claims incurred but not reported are estimated based on the Company’s historical experience, which is continually monitored, and accruals are adjusted when warranted by changes in facts and circumstances. The Company’s actual experience may be different than its estimates, sometimes significantly. Changes in assumptions, as well as changes in actual experience could cause these estimates to change. Insurance and claims expense will vary from period to period based on the severity and frequency of claims incurred in a given period. The Company’s self-insurance reserves totaled $4.2 million and $5.8 million as of December 28, 2018 and December 29, 2017 , respectively. These accruals are recorded in Accrued Expenses and Other Long-Term Liabilities in the Consolidated Balance Sheets. Foreign Currency Contracts The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations . The Company has designated these foreign currency forward contracts as cash flow hedges. The estimated Accumulated Other Comprehensive Income related to the Company’s foreign currency contracts that is expected to be reclassified into earnings within the next twelve months is a $0.7 million loss. The impact to the Company’s results of operations from its forward contracts for fiscal years 2018 , 2017 and 2016 was as follows (in thousands): 2018 2017 2016 Increase (decrease) in sales $ (758 ) $ 1,327 $ — Increase (decrease) in cost of sales (944 ) 84 3,516 Ineffective portion of change in fair value — — — Information regarding outstanding foreign currency contracts designated as cash flow hedges as of December 28, 2018 is as follows (dollars in thousands): Aggregate Amount Start Date End Date $/Foreign Currency Fair Value Balance Sheet Location $ 12,621 Jan 2019 Jun 2019 1.1686 Euro $ (149 ) Accrued Expenses 10,991 Jan 2019 Jun 2019 0.0523 Peso (494 ) Accrued Expenses 10,535 Jan 2019 Jun 2019 1.1705 Euro (141 ) Accrued Expenses 11,019 Jan 2019 Jun 2019 0.0483 Peso (316 ) Accrued Expenses 10,499 Jul 2019 Dec 2019 0.0500 Peso 368 Accrued Expenses

Earnings (Loss) Per Share

Earnings (Loss) Per Share	12 Months Ended
	Dec. 28, 2018
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	(14.) EARNINGS (LOSS) PER SHARE The following table sets forth a reconciliation of the information used in computing basic and diluted EPS for fiscal years 2018 , 2017 and 2016 (in thousands, except per share amounts): 2018 2017 2016 Numerator for basic and diluted EPS: Income from continuing operations $ 47,033 $ 87,087 $ 24,878 Income (loss) from discontinued operations 120,931 (20,408 ) (18,917 ) Net income $ 167,964 $ 66,679 $ 5,961 Denominator for basic EPS: Weighted average shares outstanding 32,136 31,402 30,778 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 460 654 195 Denominator for diluted EPS 32,596 32,056 30,973 Basic earnings (loss) per share: Income from continuing operations $ 1.46 $ 2.77 $ 0.81 Income (loss) from discontinued operations 3.76 (0.65 ) (0.61 ) Basic earnings per share 5.23 2.12 0.19 Diluted earnings (loss) per share: Income from continuing operations $ 1.44 $ 2.72 $ 0.80 Income (loss) from discontinued operations 3.71 (0.64 ) (0.61 ) Diluted earnings per share 5.15 2.08 0.19 The diluted weighted average share calculations do not include the following securities for fiscal years 2018 , 2017 and 2016 , which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): 2018 2017 2016 Time-vested stock options, restricted stock and restricted stock units 237 676 657 Performance-vested stock options and restricted stock units 144 285 357

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 28, 2018
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	(15.) ACCUMULATED OTHER COMPREHENSIVE INCOME Accumulated Other Comprehensive Income is comprised of the following (in thousands): Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount December 30, 2016 $ (1,475 ) $ 1,420 $ (15,660 ) $ (15,715 ) $ (285 ) $ (16,000 ) Unrealized gain on cash flow hedges — 3,707 — 3,707 (353 ) 3,354 Realized gain on foreign currency hedges — (1,243 ) — (1,243 ) 435 (808 ) Realized gain on interest rate swap hedges — (466 ) — (466 ) 163 (303 ) Net defined benefit plan adjustments 53 — — 53 23 76 Foreign currency translation gain — — 65,860 65,860 — 65,860 December 29, 2017 $ (1,422 ) $ 3,418 $ 50,200 $ 52,196 $ (17 ) $ 52,179 Unrealized gain on cash flow hedges — 1,904 — 1,904 (400 ) 1,504 Realized gain on foreign currency hedges — (186 ) — (186 ) 39 (147 ) Realized gain on interest rate swap hedges — (1,697 ) — (1,697 ) 356 (1,341 ) Net defined benefit plan adjustments 232 — — 232 70 302 Foreign currency translation loss — — (19,925 ) (19,925 ) — (19,925 ) Reclassifications to earnings (1) 895 — 264 1,159 (261 ) 898 Reclassification to retained earnings (2) — — — — (466 ) (466 ) December 28, 2018 $ (295 ) $ 3,439 $ 30,539 $ 33,683 $ (679 ) $ 33,004 __________ (1) Accumulated foreign currency translation losses of $0.3 million and defined benefit plan liabilities of $0.6 million (net of income taxes of $0.3 million ) were reclassified to earnings in during 2018 as a result of the divestiture of the AS&O Product Line. (2) Represents the stranded tax effects reclassified from accumulated other comprehensive income to retained earnings resulting from the adoption of ASU 2018-02 during the fourth quarter of 2018. Refer to Note 1 “Summary of Significant Accounting Policies” for discussion of the adoption of ASU 2018-02. The realized gains relating to the Company’s foreign currency hedges were reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales or Sales as the transactions they are hedging occur. The realized gains relating to the Company’s interest rate swap hedges were reclassified from Accumulated Other Comprehensive Income and included in Interest Expense as interest on the corresponding debt being hedged is accrued. Refer to Note 9 “Benefit Plans” for details on the change in net defined benefit plan adjustments.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 28, 2018
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	(16.) FAIR VALUE MEASUREMENTS Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. Foreign Currency Contracts The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. In addition to the above, the Company received fair value estimates from the foreign currency contract counterparty to verify the reasonableness of the Company’s estimates. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Sales or Cost of Sales as the inventory, which the contracts are hedging, is sold. Interest Rate Swap The fair value of the Company’s interest rate swap outstanding at December 28, 2018 was determined through the use of a cash flow model that utilized observable market data inputs. These observable market data inputs included LIBOR, swap rates, and credit spread curves. In addition to the above, the Company received a fair value estimate from the interest rate swap counterparty to verify the reasonableness of the Company’s estimate. This fair value calculation was categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s interest rate swap will be realized as a component of Interest Expense as interest on the corresponding borrowings is accrued. The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 28, 2018 Assets: Interest rate swap (Note 8) $ 4,171 $ — $ 4,171 $ — Liabilities: Foreign currency contracts (Note 13) 732 — 732 — December 29, 2017 Assets: Interest rate swaps (Note 8) $ 4,279 $ — $ 4,279 $ — Liabilities: Foreign currency contracts (Note 13) 861 — 861 — Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of these items. Borrowings under the Company’s Revolving Credit Facility, TLA Facility and TLB Facility accrue interest at a floating rate tied to a standard short-term borrowing index, selected at the Company’s option, plus an applicable margin. The carrying amount of this floating rate debt approximates fair value based upon the respective interest rates adjusting with market rate adjustments. (16.) FAIR VALUE MEASUREMENTS (Continued) Equity Investments Equity investments are comprised of the following (in thousands): December 28, December 29, Equity method investment $ 15,148 $ 13,800 Non-marketable equity securities 7,667 7,008 Total equity investments $ 22,815 $ 20,808 The components of (Gain) Loss on Equity Investments, Net for each period were as follows (in thousands): 2018 2017 2016 Equity method investment income and other (1) $ (5,623 ) $ (3,685 ) $ (737 ) Impairment charges (2) — 5,250 1,570 Total (gain) loss on equity investments, net $ (5,623 ) $ 1,565 $ 833 __________ (1) Equity method investment income and other includes the Company’s share of equity method investee gains (losses) and realized gains on sales of non-marketable equity investments. (2) Prior to the adoption of ASU 2016-01, the Company accounted for its non-marketable equity securities under the cost method of accounting. The other than temporary impairment charges during 2017 and 2016 relate to non-marketable equity securities under the cost method of accounting. There were no observable price adjustments on non-marketable equity securities related to the adoption of ASU 2016-01 in 2018 and this is not applicable in prior periods. Equity method investments and non-marketable equity securities, as described above, are included within Level 2 of the fair value hierarchy. The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. As of December 28, 2018 , the Company owned 6.7% of this fund. Pension Plan Assets The fair value of the Company’s pension plan assets disclosed in Note 9 “Benefit Plans” are determined based upon quoted market prices in inactive markets or valuation models with observable market data inputs to estimate fair value. These observable market data inputs include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and reference data. The Company’s pension plan assets are categorized Level 2 of the fair value hierarchy.

Segment and Geographic Informat

Segment and Geographic Information	12 Months Ended
	Dec. 28, 2018
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHIC INFORMATION	The following table presents sales by customer for fiscal year 2018 . Customer Medical Non-Medical Customer A 22 % — % Customer B 19 % — % Customer C 12 % — % Customer D — % 28 % All other customers 47 % 72 % (17.) SEGMENT AND GEOGRAPHIC INFORMATION The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker (“CODM”), to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting . The Company defines segment income from operations as sales less cost of sales including amortization and expenses attributable to segment-specific selling, general, administrative, research, development, engineering and other operating activities. The remaining unallocated operating and other expenses are primarily administrative corporate headquarter expenses and capital costs that are not allocated to reportable segments. Transactions between the two segments are not significant. (17.) SEGMENT AND GEOGRAPHIC INFORMATION (Continued) The following table presents sales by product line for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Segment sales by product line: Medical Cardio & Vascular $ 585,464 $ 530,831 $ 484,891 Cardiac & Neuromodulation 443,347 428,275 439,375 Advanced Surgical, Orthopedics & Portable Medical 133,225 120,006 109,557 Total Medical 1,162,036 1,079,112 1,033,823 Non-Medical 52,976 56,968 41,679 Total sales $ 1,215,012 $ 1,136,080 $ 1,075,502 A significant portion of the Company’s sales for fiscal years 2018 , 2017 and 2016 and accounts receivable at December 28, 2018 and December 29, 2017 were to three customers as follows: Sales Accounts Receivable 2018 2017 2016 December 28, December 29, Customer A 21% 22% 24% 11% 11% Customer B 19% 20% 21% 18% 21% Customer C 12% 11% 12% 20% 20% 52% 53% 57% 49% 52% The following table presents income from operations for the Company’s reportable segments for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Segment income from operations: Medical $ 224,893 $ 197,212 $ 170,101 Non-Medical 14,697 11,335 1,513 Total segment income from operations 239,590 208,547 171,614 Unallocated operating expenses (84,035 ) (82,898 ) (78,691 ) Operating income 155,555 125,649 92,923 Unallocated expenses, net (94,439 ) (76,390 ) (64,758 ) Income before benefit for income taxes $ 61,116 $ 49,259 $ 28,165 The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Segment depreciation and amortization: Medical $ 71,922 $ 72,314 $ 65,528 Non-Medical 1,364 2,675 2,346 Total depreciation and amortization included in segment income from operations 73,286 74,989 67,874 Unallocated depreciation and amortization 8,252 6,194 4,994 Total depreciation and amortization $ 81,538 $ 81,183 $ 72,868 (17.) SEGMENT AND GEOGRAPHIC INFORMATION (Continued) The following table presents total assets for the Company’s reportable segments as of December 28, 2018 and December 29, 2017 (in thousands). December 28, December 29, Identifiable assets: Medical (1) $ 2,186,565 $ 2,687,227 Non-Medical 53,812 54,071 Total reportable segments 2,240,377 2,741,298 Unallocated assets 86,304 107,047 Total assets $ 2,326,681 $ 2,848,345 __________ (1) Medical segment identifiable assets at December 29, 2017 includes $451.4 million of assets held sale. The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Expenditures for tangible long-lived assets: Medical $ 34,615 $ 20,896 $ 27,014 Non-Medical 573 661 1,451 Total reportable segments 35,188 21,557 28,465 Unallocated long-lived tangible assets 6,110 8,783 8,251 Total expenditures $ 41,298 $ 30,340 $ 36,716 Geographic Area Information The following table presents sales by significant country for fiscal years 2018 , 2017 and 2016 . In these tables, sales are allocated based on where the products are shipped (in thousands). 2018 2017 2016 Sales by geographic area: United States $ 687,259 $ 662,133 $ 625,670 Non-Domestic locations: Puerto Rico 146,500 140,184 162,343 Costa Rica 62,044 55,364 53,501 Rest of world 319,209 278,399 233,988 Total sales $ 1,215,012 $ 1,136,080 $ 1,075,502 The following table presents PP&E by geographic area as of December 28, 2018 and December 29, 2017 . In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands). December 28, December 29, Long-lived tangible assets by geographic area: United States $ 151,851 $ 157,808 Mexico 34,606 28,985 Ireland 32,190 33,992 Rest of world 12,622 14,395 Total $ 231,269 $ 235,180 (17.) SEGMENT AND GEOGRAPHIC INFORMATION (Continued) Disaggregation of Revenue by Segment In general, the Company's business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. Additionally, the tables below disaggregate the Company’s revenues based upon significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues, and ship to country, which is defined as any country where 10% or more of a segment’s total revenues are shipped to. The Company believes that these categories best depict how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. The following table presents sales by customer for fiscal year 2018 . Customer Medical Non-Medical Customer A 22 % — % Customer B 19 % — % Customer C 12 % — % Customer D — % 28 % All other customers 47 % 72 % The following table presents revenues by ship to country for fiscal year 2018 . Ship to Location Medical Non-Medical United States 56% 66% Puerto Rico 13% —% Canada —% 11% All other Countries 31% 23%

Quarterly Sales and Earnings Da

Quarterly Sales and Earnings Data - Unaudited	12 Months Ended
	Dec. 28, 2018
Quarterly Financial Information Disclosure [Abstract]
QUARTERLY SALES AND EARNINGS DATA - UNAUDITED	QUARTERLY SALES AND EARNINGS DATA—UNAUDITED (in thousands, except per share data) Fourth Quarter Third Quarter Second Quarter First Quarter Fiscal Year 2018 Sales $ 303,034 $ 305,088 $ 314,464 $ 292,426 Gross profit 88,445 91,923 98,765 83,532 Net income (loss) 19,196 (8,303 ) (1) 23,056 13,084 EPS—basic 0.59 (0.26 ) 0.72 0.41 EPS—diluted 0.58 (0.26 ) 0.70 0.40 Fiscal Year 2017 Sales $ 302,260 $ 286,168 $ 280,916 $ 266,736 Gross profit 93,621 89,186 89,175 82,028 Net income 54,698 (2) 19,882 9,559 2,948 EPS—basic 1.73 0.63 0.31 0.10 EPS—diluted 1.69 0.62 0.30 0.09 __________ (1) Includes pre-tax charges totaling $41 million for the extinguishment of debt, primarily in connection with the divestiture of the AS&O Product Line. (2) Includes one-time net tax benefit of $40 million, primarily resulting from the Tax Reform Act.

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 28, 2018
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts Disclosure	Schedule II—Valuation and Qualifying Accounts Col. C—Additions Column A Description Col. B Balance at Beginning of Period Charged to Costs & Expenses Charged to Other Accounts- Describe Col. D Deductions - Describe Col. E Balance at End of Period December 28, 2018 Allowance for doubtful accounts $ 536 $ 169 $ (2 ) (2) $ (111 ) (4) $ 592 Valuation allowance for deferred tax assets $ 36,480 $ — $ (170 ) (2) $ (1,971 ) (1)(4)(5) $ 34,339 December 29, 2017 Allowance for doubtful accounts $ 475 $ 194 $ — $ (133 ) (4) $ 536 Valuation allowance for deferred tax assets $ 35,391 $ 3,284 (1) $ — $ (2,195 ) (4)(5) $ 36,480 December 30, 2016 Allowance for doubtful accounts $ 639 $ (90 ) $ — $ (74 ) (4) $ 475 Valuation allowance for deferred tax assets $ 39,171 $ 641 (1) $ (5,135 ) (2)(3) $ 714 (5) $ 35,391 (1) Valuation allowance recorded in the provision for income taxes for certain net operating losses and tax credits. The decrease in 2018 includes the impact of the divestiture of the AS&O Product Lines. The increase in 2017 includes the impact of the adoption of the Tax Reform Act, which increased the value of our state deferred tax assets to which a corresponding valuation allowance was recorded. (2) Includes foreign currency translation effect. (3) Amount represents measurement-period adjustments related to the acquisition of LRM. (4) Accounts written off. (5) Includes return to provision adjustments for prior years.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 28, 2018
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of Integer Holdings Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Fiscal Year End	Fiscal Year The Company utilizes a fifty-two or fifty-three week fiscal year ending on the Friday nearest December 31. Fiscal years 2018 , 2017 and 2016 consisted of fifty-two weeks and ended on December 28, 2018 , December 29, 2017 and December 30, 2016 , respectively.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting periods. Actual results could differ materially from those estimates.
Reclassifications
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and accounts receivable are to four customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 17 “Segment and Geographic Information” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks.
Allowance for Doubtful Accounts	Trade Accounts Receivable and Allowance for Doubtful Accounts The Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains an allowance for those customer receivables that it does not expect to collect. The Company accrues its estimated losses from uncollectable accounts receivable to the allowance based upon recent historical experience, the length of time the receivable has been outstanding and other specific information as it becomes available. Provisions to the allowance for doubtful accounts are charged to current operating expenses. Actual losses are charged against this allowance when incurred.
Inventories	Inventories Inventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held as well as estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4 “Inventories” contains additional information on the Company’s inventory.
Property, Plant and Equipment	Property, Plant and Equipment (“PP&E”) PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 12 - 30 years; machinery and equipment 3 - 10 years; office equipment 3 - 10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, if less. The cost of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. The Company also reviews its PP&E for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its fixed asset(s) exceeds the related undiscounted future cash flows. In cases where the carrying value of the Company's long-lived assets or asset groups (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. Note 5 “Property, Plant and Equipment, Net” contains additional information on the Company’s PP&E.
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e . the “exit price”) in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) 820, Fair Value Measurements, establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows: Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment. Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market. Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations. Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 16 “Fair Value Measurements” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements.
Business Combinations	Acquisitions Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. All direct acquisition-related costs are expensed as incurred. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.
Goodwill	Goodwill Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired and is assigned to one or more reporting units. The Company tests each reporting unit’s goodwill for impairment at least annually as of the last day of the fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. In conducting its goodwill test, the Company first performs a qualitative assessment, which requires that it consider events or circumstances including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, changes in strategy, changes in customers, changes in the Company’s stock price, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair values of its reporting units are greater than the carrying amounts, then the quantitative goodwill impairment test is not performed. If the qualitative assessment indicates that the quantitative analysis should be performed, the Company then evaluates goodwill for impairment by comparing the fair value of each of its reporting units to its carrying value, including the associated goodwill. To determine the fair values, the Company uses a weighted combination of the market approach based on comparable publicly traded companies and the income approach based on estimated discounted future cash flows. The cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. The Company completed its annual goodwill impairment test as of December 28, 2018 and determined, after performing a qualitative review of each reporting unit, that it is more likely than not that the fair value of each of its reporting units exceeds the respective carrying amounts. Accordingly, there was no indication of impairment and the quantitative goodwill impairment test was not performed. The Company does not believe that either of its reporting units are at risk for impairment.
Other Intangible Assets	Other Intangible Assets Other intangible assets consist of purchased technology and patents, customer lists and trademarks. Definite-lived intangible assets are amortized on an accelerated or straight-line basis, which approximates the projected cash flows used to determine the fair value of those definite-lived intangible assets at the time of acquisition, as follows: purchased technology and patents 5 - 15 years; customer lists 7 - 20 years and other intangible assets 1 - 10 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized. The Company expenses the costs incurred to renew or extend the term of intangible assets. The Company reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) The Company assesses its indefinite-lived intangible assets for impairment periodically to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived intangible asset to its carrying value. The fair value is determined using the income approach. Refer to Note 6 “Goodwill and Other Intangible Assets, Net” for further details of the Company’s goodwill and other intangible assets.
Cost and Equity Method Investments	Investments The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other Assets on the Consolidated Balance Sheets. Equity investments are measured and recorded as follows: • Non-marketable equity securities are equity securities without readily determinable fair value are measured and recorded at fair value with changes in fair value recognized within net income. The Company has elected the practicability exception to use an alternative that measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. Prior to fiscal 2018, these securities were accounted for using the cost method of accounting, measured at cost less other-than-temporary impairment. • Equity method investments are equity securities in investees the Company does not control but over which it has the ability to exercise influence. Equity method investments are measured at cost minus impairment, if any, plus or minus our share of equity method investee income or loss. Realized and unrealized gains and losses resulting from changes in fair value or the sale of these equity investments is recorded through (Gain) Loss on Equity Investments, Net. The carrying value of the Company’s non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities by the same issuer. Determining whether an observed transaction is similar to a security within the Company’s portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of the Company’s equity securities as a result of observable price changes requires quantitative assessments of the fair value of these securities using various valuation methodologies and involves the use of estimates. Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. The Company’s quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative factors considered include the investee's financial condition and business outlook, market for technology, operational and financing cash flow activities, technology and regulatory approval progress, and other relevant events and factors affecting the investee. When indicators of impairment exist, quantitative assessments of the fair value of the Company’s non-marketable equity investments are prepared. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. • Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security's fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. Prior to 2018, non-marketable equity securities were tested for impairment using the other-than-temporary impairment model. • Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and the Company’s ability and intent to hold the investment for a sufficient period of time to allow for recovery. The Company has determined that its investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant. Refer to Note 16 “Fair Value Measurements” for additional information on the Company’s equity investments.
Debt Issuance Costs and Discounts	Debt Issuance Costs and Discounts Debt issuance costs and discounts associated with the issuance of debt by the Company are deferred and amortized over the lives of the related debt. Debt issuance costs incurred in connection with the Company’s issuance of its revolving credit facility are classified within Other Assets and amortized to Interest Expense on a straight-line basis over the contractual term of the credit facility. Debt issuance costs and discounts related to the Company’s term-debt are recorded as a reduction of the carrying value of the related debt and are amortized to Interest Expense using the effective interest method over the period from the date of issuance to the put option date (if applicable) or the maturity date, whichever is earlier. The amortization of debt issuance costs and discounts are included in Debt Related Charges Included in Interest Expense in the Consolidated Statements of Cash Flows. Upon prepayment of the related debt, the Company accelerates the recognition of a proportionate amount of the costs as refinancing or extinguishment of debt. Note 8 “Debt” contains additional information on the Company’s debt issuance costs and discounts.
Income Taxes	Income Taxes The consolidated financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined, within each taxing jurisdiction, that it is more likely than not that the asset will not be realized. The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision (Benefit) for Income Taxes. Penalties, if incurred, are recognized as a component of Selling, General and Administrative Expenses (“SG&A”). The Company and its subsidiaries file a consolidated U.S. federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates.
Derivative Financial Instruments	Derivative Financial Instruments The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value . Changes in the fair value of derivative instruments are recorded in earnings unless hedge accounting criteria are met. The Company designated its interest rate swap (refer to Note 8 “Debt”) and foreign currency contracts (refer to Note 13 “Commitments and Contingencies”) entered into as cash flow hedges. The effective portion of the changes in fair value of these cash flow hedges is recorded each period, net of tax, in Accumulated Other Comprehensive Income until the related hedged transaction occurs. Any ineffective portion of the changes in fair value of these cash flow hedges is recorded in earnings. In the event the hedged cash flow for forecasted transactions does not occur, or it becomes probable that they will not occur, the Company reclassifies the amount of any gain or loss on the related cash flow hedge to income (expense) at that time. Cash flows related to these derivative financial instruments are included in cash flows from operating activities. The cash flows from the termination of interest rate swap agreements are reported as operating activities in the Consolidated Statements of Cash Flows.
Revenue Recognition	Revenue Recognition
Environmental Costs	Environmental Costs Environmental expenditures that relate to an existing condition caused by past operations and that do not provide future benefits are expensed as incurred. Liabilities are recorded when environmental assessments are made, the requirement for remedial efforts is probable and the amount of the liability can be reasonably estimated. Liabilities are recorded generally no later than the completion of feasibility studies. The Company has an ongoing monitoring and identification process to assess how the activities, with respect to known exposures, are progressing against the recorded liabilities, as well as to identify other potential remediation sites that are presently unknown.
Restructuring Expenses	Restructuring Expenses The Company continually evaluates alternatives to align the business with the changing needs of its customers and to lower operating costs. This includes the realignment of its existing manufacturing capacity, facility closures, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in employees receiving voluntary or involuntary employee termination benefits, which may be pursuant to contractual agreements. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. All other exit costs are expensed as incurred. Refer to Note 11 “Other Operating Expenses” for additional information.
Product Warranties	Product Warranties The Company allows customers to return defective or damaged products for credit, replacement, or repair. The Company warrants that its products will meet customer specifications and will be free from defects in materials and workmanship . The Company accrues its estimated exposure to warranty claims, through Cost of Sales, based upon recent historical experience and other specific information as it becomes available. Note 13 “Commitments and Contingencies” contains additional information on the Company’s product warranties.
Research, Development and Engineering Costs, Net (RD&E)	Research, Development and Engineering Costs (“RD&E”) RD&E costs are expensed as incurred. The primary costs are salary and benefits for personnel, material costs used in development projects and subcontracting costs.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation expense for its related compensation plans, which include stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”). For the Company's PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of targets based on market-based conditions, such as total shareholder return, or financial metrics based on the Company’s operating results. The Company recognizes forfeitures of equity awards as incurred. The fair value of the stock-based compensation is determined at the grant date. The Company uses the Black-Scholes standard option pricing model (“Black-Scholes model”) to determine the fair value of stock options. The fair value of each RSU and RSA is determined based on the Company's closing stock price on the date of grant. The fair value of each PRSU is determined based on either the Company's closing stock price on the date of grant or through a Monte Carlo simulation valuation model (“Monte Carlo model”) for those awards that include a market-based condition. In addition to the closing stock price on the date of grant, the determination of the fair value of awards using both the Black-Scholes and Monte Carlo models is affected by other assumptions, including the following: Expected Term - The Company analyzes historical employee exercise and termination data to estimate the expected term assumption for stock options. For market-based awards, the term is commensurate with the performance period remaining as of the grant date. Risk-free Interest Rate - A risk-free rate is based on the U.S. Treasury rates in effect on the grant date for a maturity equal to or approximating the expected term of the award. Expected Volatility - For stock options, expected volatility is calculated using historical volatility based on the daily closing prices of the Company's common stock over a period equal to the expected term. For market-based awards, a combination of historical and implied volatilities for the Company and members of its peer group are used in developing the expected volatility assumption. Dividend Yield - The dividend yield assumption is based on the Company’s history and the expected annual dividend yield on the grant date. The Company recognizes compensation expense based on the fair value of the award on the date of grant. For stock options, RSAs and RSUs, compensation expense is recognized over the respective service period using the straight-line amortization method. Compensation expense for PRSUs with financial metrics is reassessed each reporting period and recognized based upon the probability that the performance targets will be achieved. Compensation expense for market-based awards is not adjusted based on actual achievement of the performance goals. Based on the vesting terms of the grant, compensation expense for PRSUs is amortized over the service period using either a graded vesting method or the straight-line amortization method. The actual expense recognized over the vesting period will only be for those awards that ultimately vest, excluding market-based award considerations. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) All stock option awards granted under the Company’s compensation plans have an exercise price equal to the closing stock price on the date of grant, a ten -year contractual life and generally, vest annually over a three -year vesting term. RSUs typically vest in equal annual installments over a three or four year period. Stock options and RSAs issued to members of the Company’s Board of Directors as a portion of their annual retainer vest quarterly over a one -year vesting term. Earned PRSUs typically vest two or three years from the date of grant. The Company records deferred tax assets for awards that result in deductions on the Company's income tax returns, based on the amount of stock-based compensation expense recognized and the statutory tax rate in the jurisdiction in which it will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported on the income tax return are recorded as a component of income tax expense in the Consolidated Statements of Operations. Note 10 “Stock-Based Compensation” contains additional information on the Company’s stock-based compensation.
Foreign Currency Translation	Foreign Currency Translation and Remeasurement The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translates income and expenses at the average exchange rates in effect during the period. The net effect of this translation is recorded in the consolidated financial statements as Accumulated Other Comprehensive Income. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in the Company’s foreign subsidiaries.
Defined Benefit Plans	Defined Benefit Plans The Company recognizes in its balance sheet as an asset or liability the overfunded or underfunded status of its defined benefit plans provided to its employees located in Mexico and Switzerland. This asset or liability is measured as the difference between the fair value of plan assets, if any, and the benefit obligation of those plans. For these plans, the benefit obligation is the projected benefit obligation, which is calculated based on actuarial computations of current and future benefits for employees. Actuarial gains or losses and prior service costs or credits that arise during the period, but are not included as components of net periodic benefit expense, are recognized as a component of Accumulated Other Comprehensive Income. The Company records the service cost component of net benefit costs in Cost of Sales and Selling, General and Administrative expenses. The interest cost component of net benefit costs is recorded in Interest Expense and the remaining components of net benefit costs, amortization of net losses and expected return on plan assets, are recorded in Other (Income) Loss, Net.
Earnings (Loss) Per Share	Earnings (Loss) Per Share (“EPS”) Basic EPS is calculated by dividing Net Income (Loss) by the weighted average number of shares outstanding during the period. Diluted EPS is calculated by adjusting the weighted average number of shares outstanding for potential common shares if dilutive to the EPS calculation and consist of stock options, unvested RSAs and RSUs and, if applicable, contingently convertible instruments such as convertible debt. Note 14 “Earnings (Loss) Per Share” contains additional information on the computation of the Company’s EPS.
Comprehensive Income (Loss)	Comprehensive Income (Loss) The Company’s comprehensive income (loss) as reported in the Consolidated Statements of Comprehensive Income (Loss) includes net income (loss), foreign currency translation adjustments, the net change in cash flow hedges, and defined benefit plan liability adjustments.
Recently Issued Accounting Pronouncements	(1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Recent Accounting Pronouncements In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements. Recently Adopted Accounting Guidance On May 28, 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers,” requiring an entity to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance provided alternative methods of adoption. Subsequent guidance issued after May 2014 did not change the core principle of ASU 2014-09. The Company adopted the new guidance in the first quarter of fiscal 2018, using the modified retrospective transition method applied to those contracts which were not completed as of December 30, 2017. Prior period amounts have not been adjusted and continue to be reflected in accordance with the Company’s historical accounting. The adoption of this ASU did not have an impact on the consolidated financial statements and therefore no cumulative adjustment was recorded to equity. The Company has updated its internal controls for changes and expanded disclosures have been made in the Notes to the Financial Statements as a result of adopting the standard. Refer to Note 17, “Segment and Geographic Information for additional revenue disclosures. ASU 2016-01, “Financial Instruments - Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities,” became effective prospectively for the Company in the first quarter of fiscal 2018. This ASU requires entities to carry all investments in equity securities, including other ownership interests such as partnerships, unincorporated joint ventures, and limited liability companies, at fair value with changes in fair value recognized within net income. This ASU does not apply to equity method investments, investments that result in consolidation of the investee or investments in certain investment companies. For investments in equity securities without a readily determinable fair value, an entity is permitted to elect a practicability exception, under which the investment will be measured at cost, less impairment, plus or minus observable price changes from orderly transactions of an identical or similar investment of the same issuer. Additionally, this ASU eliminated the requirement to assess whether an impairment of an equity investment is other than temporary. The impairment model for equity investments subject to this election is now a single-step model whereby an entity performs a qualitative assessment to identify impairment. If the qualitative assessment indicates that an impairment exists, the entity would estimate the fair value of the investment and recognize in net income an impairment loss equal to the difference between the fair value and the carrying amount of the equity investment. The Company’s non-marketable equity securities formerly classified as cost method investments are measured and recorded using the measurement alternative. The Company has elected the practicability exception whereby these investments are measured at cost, less impairment, plus or minus observable price changes from orderly transactions of identical or similar investments of the same issuer. Refer to Note 16 “Fair Value Measurements” for additional information on the Company’s equity investments. In February 2018, the FASB issued ASU 2018-02, “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income,” which allows for the reclassification of certain income tax effects related to the U.S. Tax Cuts and Jobs Act (the “Tax Reform Act”) between accumulated other comprehensive income and retained earnings, thereby eliminating the stranded tax effects that were created as a result of the reduction of the U.S. federal corporate income tax rate. The effective date of this ASU for the Company is the first quarter of fiscal 2019, with early adoption permitted. The Company elected to early adopt this ASU during the fourth quarter of fiscal 2018 and reclassified the related tax effects from the change in the federal corporate tax from accumulated other comprehensive income to retained earnings. The reclassification was adopted on a prospective basis and is reflected in the Consolidated Statements of Stockholders’ Equity. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Recent Accounting Pronouncements Not Yet Effective

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 28, 2018
Discontinued Operations and Disposal Groups [Abstract]
Summary of discontinued operations	In connection with the Spin-off, during the first quarter of 2016, the Company made a cash capital contribution of $75 million to Nuvectra and divested assets of $130.8 million and liabilities of $2.1 million .

Divestiture and Acquisition (Ta

Divestiture and Acquisition (Tables)	12 Months Ended
	Dec. 28, 2018
Divestiture and Acquisition [Abstract]
Summary of divested assets and liabilities	In connection with the Spin-off, during the first quarter of 2016, the Company made a cash capital contribution of $75 million to Nuvectra and divested assets of $130.8 million and liabilities of $2.1 million .

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 28, 2018
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow	The following represents supplemental cash flow information, including supplemental information related to discontinued operations, for fiscal years 2018 , 2017 and 2016 (in thousands): 2018 2017 2016 Noncash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 2,303 $ 3,474 $ 3,499 Cash paid (refunded) during the year for: Interest 79,661 93,839 106,475 Income taxes 23,155 (8,185 ) 7,263 Cash and cash equivalents, end of period, are comprised of: Cash and cash equivalents $ 25,569 $ 37,341 Cash included in current assets of discontinued operations held for sale — 6,755 Total cash and cash equivalents, end of period $ 25,569 $ 44,096

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 28, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories are comprised of the following (in thousands): December 28, December 29, Raw materials $ 80,213 $ 85,050 Work-in-process 75,711 63,620 Finished goods 34,152 28,068 Total $ 190,076 $ 176,738

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 28, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	comprised of the following (in thousands): December 28, 2018 December 29, Manufacturing machinery and equipment $ 261,912 $ 249,233 Buildings and building improvements 95,886 97,346 Information technology hardware and software 60,901 54,302 Leasehold improvements 61,418 58,918 Furniture and fixtures 15,082 15,068 Land and land improvements 11,544 13,146 Construction work in process 23,886 19,758 Other 1,048 829 531,677 508,600 Accumulated depreciation (300,408 ) (273,420 ) Total $ 231,269 $ 235,180
Depreciation Expense Disclosure	Depreciation expense for PP&E was as follows for fiscal years 2018 , 2017 and 2016 (in thousands): 2018 2017 2016 Depreciation expense $ 40,078 $ 38,077 $ 37,398

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 28, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The change in the carrying amount of goodwill by reportable segment during fiscal year 2018 was as follows (in thousands): Medical Non-Medical Total December 29, 2017 $ 822,870 $ 17,000 $ 839,870 Foreign currency translation (7,532 ) — (7,532 ) December 28, 2018 $ 815,338 $ 17,000 $ 832,338
Schedule of Finite-Lived Intangible Assets	ntangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Net Carrying Amount December 28, 2018 Definite-lived: Purchased technology and patents $ 241,726 $ (125,540 ) $ 116,186 Customer lists 710,406 (104,556 ) 605,850 Other 3,503 (3,489 ) 14 Total amortizing intangible assets $ 955,635 $ (233,585 ) $ 722,050 Indefinite-lived: Trademarks and tradenames $ 90,288 December 29, 2017 Definite-lived: Purchased technology and patents $ 243,679 $ (111,185 ) $ 132,494 Customer lists 718,649 (78,621 ) 640,028 Other 4,660 (4,597 ) 63 Total amortizing intangible assets $ 966,988 $ (194,403 ) $ 772,585 Indefinite-lived: Trademarks and tradenames $ 90,288
Schedule of Indefinite-Lived Intangible Assets	Intangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Net Carrying Amount December 28, 2018 Definite-lived: Purchased technology and patents $ 241,726 $ (125,540 ) $ 116,186 Customer lists 710,406 (104,556 ) 605,850 Other 3,503 (3,489 ) 14 Total amortizing intangible assets $ 955,635 $ (233,585 ) $ 722,050 Indefinite-lived: Trademarks and tradenames $ 90,288 December 29, 2017 Definite-lived: Purchased technology and patents $ 243,679 $ (111,185 ) $ 132,494 Customer lists 718,649 (78,621 ) 640,028 Other 4,660 (4,597 ) 63 Total amortizing intangible assets $ 966,988 $ (194,403 ) $ 772,585 Indefinite-lived: Trademarks and tradenames $ 90,288
Schedule of Finite-Lived Intangible Assets, Amortization Expense	Aggregate intangible asset amortization expense is comprised of the following for fiscal years 2018 , 2017 and 2016 (in thousands): 2018 2017 2016 Cost of sales $ 14,134 $ 15,183 $ 15,368 SG&A 26,658 24,840 19,590 RD&E 154 545 512 Other Operating Expenses (“OOE”) 514 2,538 — Total intangible asset amortization expense $ 41,460 $ 43,106 $ 35,470
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future intangible asset amortization expense based upon the carrying value as of December 28, 2018 is as follows (in thousands): 2019 2020 2021 2022 2023 After 2023 Amortization Expense $ 40,200 $ 40,511 $ 39,658 $ 38,623 $ 36,779 $ 526,279

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 28, 2018
Accounts Payable and Accrued Liabilities [Abstract]
Schedule of Accrued Liabilities	Accrued expenses are comprised of the following (in thousands): December 28, 2018 December 29, Salaries and benefits $ 21,830 $ 25,103 Profit sharing and bonuses 22,912 13,625 Product warranties 2,600 2,820 Deferred revenue 2,482 1,610 Accrued interest 1,944 8,523 Other 8,722 8,695 Total $ 60,490 $ 60,376

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 28, 2018
Debt Disclosure [Abstract]
Schedule of Debt	Long-term debt is comprised of the following (in thousands): December 28, 2018 December 29, Senior secured term loan A $ 304,687 $ 335,157 Senior secured term loan B 632,286 873,286 9.125% senior notes due 2023 — 360,000 Revolving line of credit 5,000 74,000 Unamortized discount on term loan B and debt issuance costs (16,466 ) (33,278 ) Total debt 925,507 1,609,165 Current portion of long-term debt (37,500 ) (30,469 ) Total long-term debt $ 888,007 $ 1,578,696
Schedule of Maturities of Long-term Debt	Contractual maturities of the Company’s debt facilities for the next five years and thereafter, excluding any discounts or premiums, as of December 28, 2018 are as follows (in thousands): 2019 2020 2021 2022 After 2022 Future minimum principal payments $ 37,500 42,500 229,687 632,286 —
Schedule of Deferred Financing Costs	The change in deferred debt issuance costs related to the Company’s Revolving Credit Facility is as follows (in thousands): December 30, 2016 $ 3,800 Amortization during the period (992 ) December 29, 2017 2,808 Amortization during the period (991 ) December 28, 2018 $ 1,817 The change in unamortized discount and debt issuance costs related to the Term Loan Facilities and Senior Notes is as follows (in thousands): Debt Issuance Costs Unamortized Discount on TLB Facility Total December 30, 2016 $ 32,096 $ 8,741 $ 40,837 Financing costs incurred 2,360 — 2,360 Write-off of debt issuance costs and unamortized discount (1) (2,421 ) (1,104 ) (3,525 ) Amortization during the period (5,146 ) (1,248 ) (6,394 ) December 29, 2017 26,889 6,389 33,278 Write-off of debt issuance costs and unamortized discount (1) (9,757 ) (1,610 ) (11,367 ) Amortization during the period (4,419 ) (1,026 ) (5,445 ) December 28, 2018 $ 12,713 $ 3,753 $ 16,466
Schedule of Interest Rate Derivatives	regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of December 28, 2018 is as follows (dollars in thousands): Notional Amount Start Date End Date Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun-17 Jun-20 1.1325 % 2.5063% $ 4,171 Other Assets The estima

Benefit Plans (Tables)

Benefit Plans (Tables)	12 Months Ended
	Dec. 28, 2018
Defined Benefit Plan [Abstract]
Schedule of Projected Benefit Obligation and Fair Value of Plan Assets	Information relating to the funding position of the Company’s defined benefit plans for fiscal years 2018 and 2017 were as follows (in thousands): 2018 2017 Change in projected benefit obligation: Projected benefit obligation at beginning of year $ 2,608 $ 2,285 Service cost 214 200 Interest cost 48 42 Plan participants’ contribution 84 75 Actuarial gain (150 ) (90 ) Benefits (paid) transferred in, net 42 (11 ) Settlements (619 ) — Foreign currency translation (24 ) 107 Projected benefit obligation at end of year 2,203 2,608 Change in fair value of plan assets: Fair value of plan assets at beginning of year 1,358 1,172 Employer contributions 83 56 Plan participants’ contributions 84 75 Actual loss on plan assets (11 ) — Benefits transferred in, net 62 — Settlements (619 ) — Foreign currency translation (11 ) 55 Fair value of plan assets at end of year 946 1,358 Projected benefit obligation in excess of plan assets at end of year $ 1,257 $ 1,250 Defined benefit liability classified as other current liabilities $ 54 $ 32 Defined benefit liability classified as long-term liabilities $ 1,203 $ 1,218 Accumulated benefit obligation at end of year $ 1,809 $ 2,189
Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)	Amounts recognized in Accumulated Other Comprehensive Income (Loss) for fiscal years 2018 and 2017 are as follows (in thousands): 2018 2017 Net (gain) loss occurring during the year $ (130 ) $ 74 Amortization of losses (101 ) (45 ) Prior service cost 1 1 Amortization of prior service cost (2 ) (2 ) Pre-tax adjustment (gain) loss (232 ) 28 Tax benefit (70 ) (5 ) Net (gain) loss $ (302 ) $ 23
Schedule of Amounts in Accumulated Other Comprehensive Income (Loss) to be Recognized over Next Fiscal Year	The amortization of amounts in Accumulated Other Comprehensive Income expected to be recognized as components of net periodic benefit expense during fiscal year 2019 are as follows (in thousands): Amortization of net prior service cost $ 1 Amortization of net loss 5
Schedule of Net Benefit Costs	Net pension cost for fiscal years 2018 and 2017 is comprised of the following (in thousands): 2018 2017 2016 Service cost $ 214 $ 200 $ 173 Interest cost 48 42 36 Settlements loss 69 — — Expected return on assets (17 ) (19 ) (18 ) Recognized net actuarial loss 33 44 38 Net pension cost $ 347 $ 267 $ 229
Schedule of Assumptions Used	The weighted-average rates used in the actuarial valuations to determine the net pension cost for fiscal years 2018 , 2017 and 2016 were as follows: 2018 2017 2016 Discount rate 3.1% 2.9% 2.3% Salary growth 3.2% 3.1% 2.4% Expected rate of return on assets 1.3% 1.5% 2.0% The weighted-average rates used in the actuarial valuations to determine the projected benefit obligation for fiscal years 2018 , 2017 and 2016 were as follows: 2018 2017 2016 Discount rate 6.0% 3.1% 2.9% Salary growth 4.1% 3.2% 3.1% Expected rate of return on assets 1.4% 1.3% 1.5%
Schedule of Allocation of Plan Assets	The following table provides information by level for the defined benefit plan assets that are measured at fair value as of December 28, 2018 and December 29, 2017 (in thousands). Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 28, 2018 Insurance contract $ 946 $ — $ 946 $ — December 29, 2017 Insurance contract $ 1,358 $ — $ 1,358 $ —
Schedule of Expected Benefit Payments	Estimated benefit payments over for the next ten years as of December 28, 2018 are as follows (in thousands): 2019 2020 2021 2022 2023 2024-2028 Estimated benefit payments $ 104 121 124 134 145 964

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 28, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The components and classification of stock-based compensation expense for fiscal years 2018 , 2017 and 2016 were as follows (in thousands): 2018 2017 2016 Stock options $ 873 $ 1,633 $ 2,455 RSAs and RSUs (time-based) 6,024 4,952 1,764 PRSUs 3,159 6,867 3,887 Stock-based compensation expense - continuing operations 10,056 $ 13,452 $ 8,106 Discontinued operations 414 1,228 302 Total stock-based compensation expense $ 10,470 $ 14,680 $ 8,408 Cost of sales $ 849 $ 748 $ 208 SG&A 9,090 9,893 6,086 RD&E 112 642 337 OOE 5 2,169 1,475 Discontinued operations 414 1,228 302 Total stock-based compensation expense $ 10,470 $ 14,680 $ 8,408
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The following table includes the weighted average grant date fair value of stock options granted to employees during fiscal years 2018 , 2017 and 2016 and the related weighted average assumptions used in the Black-Scholes model: 2018 2017 2016 Weighted average fair value of options granted $ 14.89 $ 12.86 $ 8.52 Assumptions: Expected term (in years) 4.0 4.5 4.7 Risk-free interest rate 2.21 % 1.77 % 1.49 % Expected volatility 39 % 37 % 27 % Expected dividend yield 0 % 0 % 0 %
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes stock option activity during the fiscal year ended December 28, 2018 : Number of Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in millions) Outstanding at December 29, 2017 931,353 $ 30.89 Granted 28,447 45.13 Exercised (413,317 ) 30.02 Forfeited or expired (23,700 ) 41.28 Outstanding at December 28, 2018 522,783 $ 31.88 5.8 $ 23.1 Vested and expected to vest at December 28, 2018 522,783 $ 31.88 5.8 $ 23.1 Exercisable at December 28, 2018 488,468 $ 31.37 5.6 $ 21.8
Schedule Of Stock Option Exercise Information	The following table provides certain information relating to the exercise of stock options during fiscal years 2018 , 2017 and 2016 (in thousands): 2018 2017 2016 Intrinsic value $ 17,722 $ 13,928 $ 690 Cash received 12,409 19,324 2,821
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes time-vested RSA and RSU activity during the fiscal year ended December 28, 2018 : Time-Vested Restricted Stock Units and Awards Weighted Average Grant Date Fair Value Nonvested at December 29, 2017 163,431 $ 35.96 Granted 167,514 52.14 Vested (134,423 ) 38.88 Forfeited (54,286 ) 42.44 Nonvested at December 28, 2018 142,236 $ 49.78 The following table summarizes the maximum number of PRSUs which could be earned and related activity during the fiscal year ended December 28, 2018 : Performance- Vested Restricted Stock Units and Awards Weighted Average Grant Date Fair Value Nonvested at December 29, 2017 469,889 $ 32.37 Granted 159,669 45.37 Vested (161,674 ) 35.28 Forfeited (180,750 ) 35.24 Nonvested at December 28, 2018 287,134 $ 36.15

Other Operating Expenses (Table

Other Operating Expenses (Tables)	12 Months Ended
	Dec. 28, 2018
Restructuring Cost and Reserve [Line Items]
Schedule of Other Operating Cost and Expense, by Component	OOE for fiscal years 2018 , 2017 and 2016 is comprised of the following (in thousands): 2018 2017 2016 Strategic reorganization and alignment $ 10,624 $ 5,891 $ — Manufacturing alignment to support growth 3,089 — — Consolidation and optimization initiatives 844 12,803 25,510 Acquisition and integration costs — 10,870 28,112 Asset dispositions, severance and other 1,508 6,874 6,791 Other operating expenses $ 16,065 $ 36,438 $ 60,413
Consolidation and optimization initiatives [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve by Type of Cost	Severance and Retention Accelerated Depreciation/ Asset Write-offs Other Total December 29, 2017 $ 1,308 $ — $ — $ 1,308 Restructuring charges 3,812 514 10,231 14,557 Write-offs — (514 ) — (514 ) Cash payments (3,452 ) — (10,029 ) (13,481 ) December 28, 2018 $ 1,668 $ — $ 202 $ 1,870

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 28, 2018
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	2018 , 2017 and 2016 consisted of the following (in thousands): 2018 2017 2016 U.S. $ (4,273 ) $ 306 $ (12,547 ) International 65,389 48,953 40,712 Total income before income taxes from continuing operations $ 61,116 $ 49,259 $ 28,165
Schedule of Components of Income Tax Expense (Benefit)	The provision (benefit) for income taxes from continuing operations for fiscal years 2018 , 2017 and 2016 was comprised of the following from continuing operations (in thousands): 2018 2017 2016 Current: Federal $ 80 $ (1,558 ) $ (8,327 ) State 166 (29 ) 149 International 9,490 8,539 7,230 9,736 6,952 (948 ) Deferred: Federal 6,610 (45,114 ) 5,457 State 103 (295 ) 527 International (2,366 ) 629 (1,749 ) 4,347 (44,780 ) 4,235 Total provision (benefit) for income taxes $ 14,083 $ (37,828 ) $ 3,287
Schedule of Effective Income Tax Rate Reconciliation	The provision (benefit) for income taxes from continuing operations differs from the U.S. statutory rate for fiscal years 2018 , 2017 and 2016 due to the following: 2018 2017 2016 Statutory rate $ 12,834 21.0 % $ 17,240 35.0 % $ 9,858 35.0 % Federal tax credits (1,700 ) (2.8 ) (1,674 ) (3.4 ) (1,570 ) (5.6 ) Foreign rate differential (6,040 ) (9.9 ) (12,934 ) (26.3 ) (9,665 ) (34.3 ) Uncertain tax positions 147 0.2 34 0.1 219 0.8 State taxes, net of federal benefit 975 1.6 (543 ) (1.1 ) (311 ) (1.1 ) U.S. tax on foreign earnings 10,473 17.1 1,471 3.0 1,508 5.4 Valuation allowance (567 ) (0.9 ) 1,030 2.1 1,273 4.5 Tax Reform Act 11 — (39,394 ) (80.0 ) — — Change in tax rates — — — — (270 ) (1.0 ) Non-deductible transaction costs — — — — 1,012 3.6 Change in tax law (Internal Revenue Code §987) — — — — 2,630 9.3 Other (2,050 ) (3.3 ) (3,058 ) (6.2 ) (1,397 ) (5.0 ) Effective tax rate $ 14,083 23.0 % $ (37,828 ) (76.8 )% $ 3,287 11.7 %
Schedule of Deferred Tax Assets and Liabilities	erred tax liability, including discontinued operations at December 29, 2017, consists of the following (in thousands): December 28, December 29, Net operating loss carryforwards $ 18,088 $ 107,005 Tax credit carryforwards 24,593 28,215 Inventories 3,408 4,956 Accrued expenses 39 3,815 Stock-based compensation 2,340 5,531 Gross deferred tax assets 48,468 149,522 Less valuation allowance (34,339 ) (36,480 ) Net deferred tax assets 14,129 113,042 Property, plant and equipment (9,445 ) (27,547 ) Intangible assets (198,648 ) (219,576 ) Convertible subordinated notes — (806 ) Other (6,009 ) (6,325 ) Gross deferred tax liabilities (214,102 ) (254,254 ) Net deferred tax liability $ (199,973 ) $ (141,212 ) Presented as follows: Noncurrent deferred tax asset $ 3,937 $ 4,152 Noncurrent deferred tax liability (203,910 ) (145,364 ) Net deferred tax liability $ (199,973 ) $ (141,212 )
Schedule of Deferred Tax Liabilities by Balance Sheet Account [Table Text Block]	The components of the net deferred tax liability, by balance sheet account, were as follows: December 28, December 29, Deferred income tax asset $ 3,937 $ 3,451 Noncurrent assets of discontinued operations held for sale — 701 Deferred income tax liabilities (203,910 ) (140,964 ) Noncurrent liabilities of discontinued operations held for sale — (4,400 ) Net deferred tax liability $ (199,973 ) $ (141,212 )
Summary of Operating Loss and Tax Credit Carryforwards	As of December 28, 2018 , the Company has the following carryforwards available: Jurisdiction Tax Attribute Amount (in millions) Begin to Expire U.S. Federal Net operating loss $ 39.1 2034 U.S. State Net operating loss 130.6 2019 International Net operating loss 31.1 2019 U.S. Federal Foreign tax credit 17.0 2019 U.S. Federal and State R&D tax credit 3.6 2019 U.S. State Investment tax credit 6.8 2019
Summary of Income Tax Contingencies	Below is a summary of changes to the unrecognized tax benefit for fiscal years 2018 , 2017 and 2016 . The amounts for 2016 and 2017 include discontinued operations. The amounts for 2018 reflect discontinued operations through the date of divestiture of the AS&O product line, which is reflected in the table below as a reduction during 2018 (in thousands): 2018 2017 2016 Balance, beginning of year $ 12,088 $ 10,561 $ 9,271 Additions based upon tax positions related to the current year 300 3,833 1,450 Additions (reductions) related to prior period tax returns (75 ) (14 ) 240 Reductions relating to settlements with tax authorities (98 ) — — Reductions relating to divestiture (6,846 ) — — Reductions as a result of a lapse of applicable statute of limitations — (510 ) — Revaluation due to change in tax rate (Tax Reform Act) — (1,782 ) — Reductions relating to business combinations — — (400 ) Balance, end of year $ 5,369 $ 12,088 $ 10,561

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 28, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranty Liability	The change in product warranty liability for fiscal years 2018 and 2017 was comprised of the following (in thousands): 2018 2017 Beginning balance $ 2,820 $ 2,764 Additions to warranty reserve, net of reversals 620 917 Warranty claims settled (840 ) (861 ) Ending balance $ 2,600 $ 2,820
Operating Leases of Lessee Disclosure	Operating lease expense for fiscal years 2018 , 2017 and 2016 was as follows (in thousands): 2018 2017 2016 Operating lease expense $ 10,753 $ 14,320 $ 12,127
Schedule of Future Minimum Rental Payments for Operating Leases	At December 28, 2018 , the Company had the following future minimum lease payments under non-cancelable operating leases (in thousands): 2019 2020 2021 2022 2023 After 2023 Future minimum lease payments $ 8,562 7,290 7,348 5,269 5,112 14,589
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The impact to the Company’s results of operations from its forward contracts for fiscal years 2018 , 2017 and 2016 was as follows (in thousands): 2018 2017 2016 Increase (decrease) in sales $ (758 ) $ 1,327 $ — Increase (decrease) in cost of sales (944 ) 84 3,516 Ineffective portion of change in fair value — — —
Schedule of Foreign Exchange Contracts, Statement of Financial Position	Information regarding outstanding foreign currency contracts designated as cash flow hedges as of December 28, 2018 is as follows (dollars in thousands): Aggregate Amount Start Date End Date $/Foreign Currency Fair Value Balance Sheet Location $ 12,621 Jan 2019 Jun 2019 1.1686 Euro $ (149 ) Accrued Expenses 10,991 Jan 2019 Jun 2019 0.0523 Peso (494 ) Accrued Expenses 10,535 Jan 2019 Jun 2019 1.1705 Euro (141 ) Accrued Expenses 11,019 Jan 2019 Jun 2019 0.0483 Peso (316 ) Accrued Expenses 10,499 Jul 2019 Dec 2019 0.0500 Peso 368 Accrued Expenses

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 28, 2018
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	for fiscal years 2018 , 2017 and 2016 (in thousands, except per share amounts):
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The diluted weighted average share calculations do not include the following securities for fiscal years 2018 , 2017 and 2016 , which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): 2018 2017 2016 Time-vested stock options, restricted stock and restricted stock units 237 676 657 Performance-vested stock options and restricted stock units 144 285 357

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 28, 2018
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income is comprised of the following (in thousands): Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount December 30, 2016 $ (1,475 ) $ 1,420 $ (15,660 ) $ (15,715 ) $ (285 ) $ (16,000 ) Unrealized gain on cash flow hedges — 3,707 — 3,707 (353 ) 3,354 Realized gain on foreign currency hedges — (1,243 ) — (1,243 ) 435 (808 ) Realized gain on interest rate swap hedges — (466 ) — (466 ) 163 (303 ) Net defined benefit plan adjustments 53 — — 53 23 76 Foreign currency translation gain — — 65,860 65,860 — 65,860 December 29, 2017 $ (1,422 ) $ 3,418 $ 50,200 $ 52,196 $ (17 ) $ 52,179 Unrealized gain on cash flow hedges — 1,904 — 1,904 (400 ) 1,504 Realized gain on foreign currency hedges — (186 ) — (186 ) 39 (147 ) Realized gain on interest rate swap hedges — (1,697 ) — (1,697 ) 356 (1,341 ) Net defined benefit plan adjustments 232 — — 232 70 302 Foreign currency translation loss — — (19,925 ) (19,925 ) — (19,925 ) Reclassifications to earnings (1) 895 — 264 1,159 (261 ) 898 Reclassification to retained earnings (2) — — — — (466 ) (466 ) December 28, 2018 $ (295 ) $ 3,439 $ 30,539 $ 33,683 $ (679 ) $ 33,004

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 28, 2018
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 28, 2018 Assets: Interest rate swap (Note 8) $ 4,171 $ — $ 4,171 $ — Liabilities: Foreign currency contracts (Note 13) 732 — 732 — December 29, 2017 Assets: Interest rate swaps (Note 8) $ 4,279 $ — $ 4,279 $ — Liabilities: Foreign currency contracts (Note 13) 861 — 861 —
Fair Value Measurements, Nonrecurring	December 28, December 29, Equity method investment $ 15,148 $ 13,800 Non-marketable equity securities 7,667 7,008 Total equity investments $ 22,815 $ 20,808

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	12 Months Ended
	Dec. 28, 2018
Segment Reporting [Abstract]
Schedule of segment sales by product line	The following table presents sales by product line for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Segment sales by product line: Medical Cardio & Vascular $ 585,464 $ 530,831 $ 484,891 Cardiac & Neuromodulation 443,347 428,275 439,375 Advanced Surgical, Orthopedics & Portable Medical 133,225 120,006 109,557 Total Medical 1,162,036 1,079,112 1,033,823 Non-Medical 52,976 56,968 41,679 Total sales $ 1,215,012 $ 1,136,080 $ 1,075,502
Schedule of Revenue by Major Customers by Reporting Segments	A significant portion of the Company’s sales for fiscal years 2018 , 2017 and 2016 and accounts receivable at December 28, 2018 and December 29, 2017 were to three customers as follows: Sales Accounts Receivable 2018 2017 2016 December 28, December 29, Customer A 21% 22% 24% 11% 11% Customer B 19% 20% 21% 18% 21% Customer C 12% 11% 12% 20% 20% 52% 53% 57% 49% 52%
Schedule of segment depreciation and amortization	The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Segment depreciation and amortization: Medical $ 71,922 $ 72,314 $ 65,528 Non-Medical 1,364 2,675 2,346 Total depreciation and amortization included in segment income from operations 73,286 74,989 67,874 Unallocated depreciation and amortization 8,252 6,194 4,994 Total depreciation and amortization $ 81,538 $ 81,183 $ 72,868
Schedule of segment income (loss) from operations	The following table presents income from operations for the Company’s reportable segments for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Segment income from operations: Medical $ 224,893 $ 197,212 $ 170,101 Non-Medical 14,697 11,335 1,513 Total segment income from operations 239,590 208,547 171,614 Unallocated operating expenses (84,035 ) (82,898 ) (78,691 ) Operating income 155,555 125,649 92,923 Unallocated expenses, net (94,439 ) (76,390 ) (64,758 ) Income before benefit for income taxes $ 61,116 $ 49,259 $ 28,165
Schedule of long-lived tangible assets and identifable assets by geographic area	The following table presents PP&E by geographic area as of December 28, 2018 and December 29, 2017 . In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands). December 28, December 29, Long-lived tangible assets by geographic area: United States $ 151,851 $ 157,808 Mexico 34,606 28,985 Ireland 32,190 33,992 Rest of world 12,622 14,395 Total $ 231,269 $ 235,180 The following table presents total assets for the Company’s reportable segments as of December 28, 2018 and December 29, 2017 (in thousands). December 28, December 29, Identifiable assets: Medical (1) $ 2,186,565 $ 2,687,227 Non-Medical 53,812 54,071 Total reportable segments 2,240,377 2,741,298 Unallocated assets 86,304 107,047 Total assets $ 2,326,681 $ 2,848,345
Schedule of expenditures for tangible long-lived assets, excluding acquisitions	The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Expenditures for tangible long-lived assets: Medical $ 34,615 $ 20,896 $ 27,014 Non-Medical 573 661 1,451 Total reportable segments 35,188 21,557 28,465 Unallocated long-lived tangible assets 6,110 8,783 8,251 Total expenditures $ 41,298 $ 30,340 $ 36,716
Schedule of sales by geographic area	The following table presents sales by significant country for fiscal years 2018 , 2017 and 2016 . In these tables, sales are allocated based on where the products are shipped (in thousands). 2018 2017 2016 Sales by geographic area: United States $ 687,259 $ 662,133 $ 625,670 Non-Domestic locations: Puerto Rico 146,500 140,184 162,343 Costa Rica 62,044 55,364 53,501 Rest of world 319,209 278,399 233,988 Total sales $ 1,215,012 $ 1,136,080 $ 1,075,502
Segment Reporting Disclosure [Text Block]	The following table presents sales by customer for fiscal year 2018 . Customer Medical Non-Medical Customer A 22 % — % Customer B 19 % — % Customer C 12 % — % Customer D — % 28 % All other customers 47 % 72 % (17.) SEGMENT AND GEOGRAPHIC INFORMATION The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker (“CODM”), to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting . The Company defines segment income from operations as sales less cost of sales including amortization and expenses attributable to segment-specific selling, general, administrative, research, development, engineering and other operating activities. The remaining unallocated operating and other expenses are primarily administrative corporate headquarter expenses and capital costs that are not allocated to reportable segments. Transactions between the two segments are not significant. (17.) SEGMENT AND GEOGRAPHIC INFORMATION (Continued) The following table presents sales by product line for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Segment sales by product line: Medical Cardio & Vascular $ 585,464 $ 530,831 $ 484,891 Cardiac & Neuromodulation 443,347 428,275 439,375 Advanced Surgical, Orthopedics & Portable Medical 133,225 120,006 109,557 Total Medical 1,162,036 1,079,112 1,033,823 Non-Medical 52,976 56,968 41,679 Total sales $ 1,215,012 $ 1,136,080 $ 1,075,502 A significant portion of the Company’s sales for fiscal years 2018 , 2017 and 2016 and accounts receivable at December 28, 2018 and December 29, 2017 were to three customers as follows: Sales Accounts Receivable 2018 2017 2016 December 28, December 29, Customer A 21% 22% 24% 11% 11% Customer B 19% 20% 21% 18% 21% Customer C 12% 11% 12% 20% 20% 52% 53% 57% 49% 52% The following table presents income from operations for the Company’s reportable segments for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Segment income from operations: Medical $ 224,893 $ 197,212 $ 170,101 Non-Medical 14,697 11,335 1,513 Total segment income from operations 239,590 208,547 171,614 Unallocated operating expenses (84,035 ) (82,898 ) (78,691 ) Operating income 155,555 125,649 92,923 Unallocated expenses, net (94,439 ) (76,390 ) (64,758 ) Income before benefit for income taxes $ 61,116 $ 49,259 $ 28,165 The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Segment depreciation and amortization: Medical $ 71,922 $ 72,314 $ 65,528 Non-Medical 1,364 2,675 2,346 Total depreciation and amortization included in segment income from operations 73,286 74,989 67,874 Unallocated depreciation and amortization 8,252 6,194 4,994 Total depreciation and amortization $ 81,538 $ 81,183 $ 72,868 (17.) SEGMENT AND GEOGRAPHIC INFORMATION (Continued) The following table presents total assets for the Company’s reportable segments as of December 28, 2018 and December 29, 2017 (in thousands). December 28, December 29, Identifiable assets: Medical (1) $ 2,186,565 $ 2,687,227 Non-Medical 53,812 54,071 Total reportable segments 2,240,377 2,741,298 Unallocated assets 86,304 107,047 Total assets $ 2,326,681 $ 2,848,345 __________ (1) Medical segment identifiable assets at December 29, 2017 includes $451.4 million of assets held sale. The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2018 , 2017 and 2016 (in thousands). 2018 2017 2016 Expenditures for tangible long-lived assets: Medical $ 34,615 $ 20,896 $ 27,014 Non-Medical 573 661 1,451 Total reportable segments 35,188 21,557 28,465 Unallocated long-lived tangible assets 6,110 8,783 8,251 Total expenditures $ 41,298 $ 30,340 $ 36,716 Geographic Area Information The following table presents sales by significant country for fiscal years 2018 , 2017 and 2016 . In these tables, sales are allocated based on where the products are shipped (in thousands). 2018 2017 2016 Sales by geographic area: United States $ 687,259 $ 662,133 $ 625,670 Non-Domestic locations: Puerto Rico 146,500 140,184 162,343 Costa Rica 62,044 55,364 53,501 Rest of world 319,209 278,399 233,988 Total sales $ 1,215,012 $ 1,136,080 $ 1,075,502 The following table presents PP&E by geographic area as of December 28, 2018 and December 29, 2017 . In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands). December 28, December 29, Long-lived tangible assets by geographic area: United States $ 151,851 $ 157,808 Mexico 34,606 28,985 Ireland 32,190 33,992 Rest of world 12,622 14,395 Total $ 231,269 $ 235,180 (17.) SEGMENT AND GEOGRAPHIC INFORMATION (Continued) Disaggregation of Revenue by Segment In general, the Company's business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. Additionally, the tables below disaggregate the Company’s revenues based upon significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues, and ship to country, which is defined as any country where 10% or more of a segment’s total revenues are shipped to. The Company believes that these categories best depict how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. The following table presents sales by customer for fiscal year 2018 . Customer Medical Non-Medical Customer A 22 % — % Customer B 19 % — % Customer C 12 % — % Customer D — % 28 % All other customers 47 % 72 % The following table presents revenues by ship to country for fiscal year 2018 . Ship to Location Medical Non-Medical United States 56% 66% Puerto Rico 13% —% Canada —% 11% All other Countries 31% 23%

Quarterly Sales and Earnings _2

Quarterly Sales and Earnings Data - Unaudited (Tables)	12 Months Ended
	Dec. 28, 2018
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	(in thousands, except per share data) Fourth Quarter Third Quarter Second Quarter First Quarter Fiscal Year 2018 Sales $ 303,034 $ 305,088 $ 314,464 $ 292,426 Gross profit 88,445 91,923 98,765 83,532 Net income (loss) 19,196 (8,303 ) (1) 23,056 13,084 EPS—basic 0.59 (0.26 ) 0.72 0.41 EPS—diluted 0.58 (0.26 ) 0.70 0.40 Fiscal Year 2017 Sales $ 302,260 $ 286,168 $ 280,916 $ 266,736 Gross profit 93,621 89,186 89,175 82,028 Net income 54,698 (2) 19,882 9,559 2,948 EPS—basic 1.73 0.63 0.31 0.10 EPS—diluted 1.69 0.62 0.30 0.09

Discontinued Operations (Assets

Discontinued Operations (Assets and Liabilities of AS&O Business) (Details) - USD ($) $ in Thousands	Jul. 02, 2018	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses	$ 581,000	$ 581,429	$ 0	$ 0
Income From Transition Services		3,600
Transition Services, Cost of Sales		200
Transition Services, Selling, General and Administrative		3,400
Current assets of discontinued operations held for sale		0	106,746
Noncurrent assets of discontinued operations held for sale		0	344,634
Current liabilities of discontinued operations held for sale		0	47,703
Deferred taxes and other long-term liabilities held for sale		0	14,966
Pre-tax Income From Discontinued Operations		195,000
Discontinued Operations, Held-for-sale [Member] | AS&O Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents		$ 0	6,755
Accounts receivable, net of allowance for doubtful accounts of $0.3 million			47,611
Inventories			50,796
Other current assets			1,584
Current assets of discontinued operations held for sale			106,746
Property, plant and equipment, net			135,195
Goodwill			150,368
Other intangible assets, net			57,520
Other noncurrent assets			1,551
Noncurrent assets of discontinued operations held for sale			344,634
Total assets divested			451,380
Accounts payable and other current liabilities held for sale			47,703
Deferred taxes and other long-term liabilities held for sale			14,966
Total liabilities			62,669
Net assets divested			$ 388,711

Revenue From Contracts With Cus

Revenue From Contracts With Customers (Disaggregated Revenue) (Details)	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Disaggregation of Revenue [Line Items]
Concentration risk percentage	52.00%	53.00%	57.00%
Medical Segment [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | Customer A [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	22.00%
Medical Segment [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | Customer B [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	19.00%
Medical Segment [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | Customer C [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	12.00%
Medical Segment [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | Customer D [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Medical Segment [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | All Other Customers [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	47.00%
Medical Segment [Member] | Revenue from Contract with Customer [Member] | Geographic Concentration Risk [Member] | United States [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	56.00%
Medical Segment [Member] | Revenue from Contract with Customer [Member] | Geographic Concentration Risk [Member] | Puerto Rico [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	13.00%
Medical Segment [Member] | Revenue from Contract with Customer [Member] | Geographic Concentration Risk [Member] | Canada [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Medical Segment [Member] | Revenue from Contract with Customer [Member] | Geographic Concentration Risk [Member] | All Other Countries [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	31.00%
Non-Medical Segment [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | Customer A [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Non-Medical Segment [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | Customer B [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Non-Medical Segment [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | Customer C [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Non-Medical Segment [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | Customer D [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	28.00%
Non-Medical Segment [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | All Other Customers [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	72.00%
Non-Medical Segment [Member] | Revenue from Contract with Customer [Member] | Geographic Concentration Risk [Member] | United States [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	66.00%
Non-Medical Segment [Member] | Revenue from Contract with Customer [Member] | Geographic Concentration Risk [Member] | Puerto Rico [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Non-Medical Segment [Member] | Revenue from Contract with Customer [Member] | Geographic Concentration Risk [Member] | Canada [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	11.00%
Non-Medical Segment [Member] | Revenue from Contract with Customer [Member] | Geographic Concentration Risk [Member] | All Other Countries [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	23.00%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Basis of Presentation) (Details) $ in Thousands	12 Months Ended
	Dec. 28, 2018USD ($)customerSegment	Dec. 29, 2017USD ($)	Dec. 30, 2016USD ($)
Accounting Policies [Abstract]
Number of Reportable Segments | Segment	2
Weeks In Reporting Period	Fifty-two	Fifty-two	Fifty-two
Number of Customers | customer	4
Schedule of Assets Useful Life [Line Items]
Cumulative effect adjustment of the adoption of ASU 2016-09		$ (510)
Net foreign currency transaction gains (losses)	$ (1,600)	(10,900)	$ 4,300
Retained Earnings [Member]
Schedule of Assets Useful Life [Line Items]
Cumulative effect adjustment of the adoption of ASU 2016-09		$ 302
Stock Options [Member]
Schedule of Assets Useful Life [Line Items]
Contractual life	10 years
Award vesting period	3 years
Restricted Stock And Unit Awards [Member] | Director [Member]
Schedule of Assets Useful Life [Line Items]
Award vesting period	1 year
Minimum [Member] | Restricted Stock And Unit Awards [Member]
Schedule of Assets Useful Life [Line Items]
Award vesting period	3 years
Minimum [Member] | Performance Based Restricted Stock And Restricted Stock Units [Member]
Schedule of Assets Useful Life [Line Items]
Award vesting period	2 years
Minimum [Member] | Patents [Member]
Schedule of Assets Useful Life [Line Items]
Intangible Asset, Useful Life	5 years
Minimum [Member] | Customer Lists [Member]
Schedule of Assets Useful Life [Line Items]
Intangible Asset, Useful Life	7 years
Minimum [Member] | Other Intangible Assets [Member]
Schedule of Assets Useful Life [Line Items]
Intangible Asset, Useful Life	1 year
Maximum [Member] | Restricted Stock And Unit Awards [Member]
Schedule of Assets Useful Life [Line Items]
Award vesting period	4 years
Maximum [Member] | Performance Based Restricted Stock And Restricted Stock Units [Member]
Schedule of Assets Useful Life [Line Items]
Award vesting period	3 years
Maximum [Member] | Patents [Member]
Schedule of Assets Useful Life [Line Items]
Intangible Asset, Useful Life	15 years
Maximum [Member] | Customer Lists [Member]
Schedule of Assets Useful Life [Line Items]
Intangible Asset, Useful Life	20 years
Maximum [Member] | Other Intangible Assets [Member]
Schedule of Assets Useful Life [Line Items]
Intangible Asset, Useful Life	10 years
Building and Building Improvements [Member] | Minimum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	12 years
Building and Building Improvements [Member] | Maximum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	30 years
Machinery and Equipment [Member] | Minimum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Office Equipment [Member] | Minimum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office Equipment [Member] | Maximum [Member]
Schedule of Assets Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	10 years

Discontinued Operations (Loss f

Discontinued Operations (Loss from Discontinued Operations) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations before taxes	$ (194,965)	$ 0	$ 0
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	188,313	(27,432)	(26,980)
Gain on sale of discontinued operations	67,382	(7,024)	(8,063)
AS&O Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales	178,020	325,841	311,276
Cost of sales	148,357	286,300	270,656
Gross profit	29,663	39,541	40,620
Selling, general and administrative expenses	8,905	18,500	16,847
Research, development and engineering costs	2,352	6,397	7,102
Other operating expenses (income)(1)	1,805	854	1,324
Interest expense	22,833	42,488	42,939
Other (income) loss, net	420	(1,266)	(612)
Gain on sale of discontinued operations	$ 67,382	$ (7,024)	$ (8,063)

Discontinued Operations Discont

Discontinued Operations Discontinued Operations (Cash Flow Information from Discontinued Operations) (Details) - USD ($) $ in Thousands	Jul. 02, 2018	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses	$ 581,000	$ 581,429	$ 0	$ 0
Income From Transition Services		3,600
Transition Services, Cost of Sales		200
Transition Services, Selling, General and Administrative		3,400
Pre-tax Income From Discontinued Operations		195,000
AS&O Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash used in operating activities		(12,498)	3,167	3,596
Cash provided by (used in) investing activities		577,833	(16,771)	(17,367)
Depreciation and amortization		7,450	21,613	17,656
Capital expenditures		$ 3,610	$ 16,844	$ 17,656

Divestiture and Acquisition (Sp

Divestiture and Acquisition (Spin-off of Nuvectra Corporation) (Details) $ in Thousands	Mar. 14, 2016	Apr. 01, 2016USD ($)	Dec. 30, 2016USD ($)	Dec. 28, 2018USD ($)	Dec. 29, 2017USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets divested in Spin-off, net of cash			$ 130,800
Liabilities divested in Spin-off			2,100
Liabilities transferred
Current liabilities				$ 0	$ 47,703
Spinoff [Member] | Nuvectra [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock conversion ratio	3
Cash capital contribution		$ 75,000
Liabilities transferred
Pre-tax loss			$ 5,200

Divestiture and Acquisition (LR

Divestiture and Acquisition (LRM - Summary of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Dec. 28, 2018	Dec. 29, 2017
Assets acquired
Goodwill	$ 832,338	$ 839,870

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Condensed Cash Flow Statements, Captions [Line Items]
Capital Expenditures Incurred but Not yet Paid	$ 2,303	$ 3,474	$ 3,499
Interest Paid, Including Capitalized Interest, Operating and Investing Activities	79,661	93,839	106,475
Income Taxes Paid, Net	23,155	(8,185)	$ 7,263
Cash and cash equivalents	25,569	37,341
Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations	25,569	44,096
Discontinued Operations, Held-for-sale [Member] | AS&O Business [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Cash and cash equivalents	$ 0	$ 6,755

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 28, 2018	Dec. 29, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 80,213	$ 85,050
Work-in-process	75,711	63,620
Finished goods	34,152	28,068
Inventories	$ 190,076	$ 176,738

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 28, 2018	Dec. 29, 2017
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 531,677	$ 508,600
Accumulated depreciation	(300,408)	(273,420)
Total	231,269	235,180
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	261,912	249,233
Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	95,886	97,346
Information Technology Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	60,901	54,302
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	61,418	58,918
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	15,082	15,068
Land and Land Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	11,544	13,146
Construction Work in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	23,886	19,758
Other [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 1,048	$ 829

Property, Plant and Equipment_4

Property, Plant and Equipment, Net (Depreciation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Property, Plant and Equipment [Abstract]
Depreciation	$ 40,078	$ 38,077	$ 37,398

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, Nets (Schedule of Goodwill) (Details)	12 Months Ended
	Dec. 28, 2018USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 839,870,000
Foreign currency translation	(7,532,000)
Ending balance	832,338,000
Medical Segment [Member]
Goodwill [Roll Forward]
Beginning balance	822,870,000
Foreign currency translation	(7,532,000)
Ending balance	815,338,000
Accumulated impairment loss	0
Non-Medical Segment [Member]
Goodwill [Roll Forward]
Beginning balance	17,000,000
Foreign currency translation	0
Ending balance	17,000,000
Accumulated impairment loss	$ 0

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, Net (Amortizing Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 28, 2018	Dec. 29, 2017
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 955,635	$ 966,988
Accumulated Amortization	(233,585)	(194,403)
Net Carrying Amount	722,050	772,585
Trademarks and Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	90,288	90,288
Purchased Technology And Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	241,726	243,679
Accumulated Amortization	(125,540)	(111,185)
Net Carrying Amount	116,186	132,494
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	710,406	718,649
Accumulated Amortization	(104,556)	(78,621)
Net Carrying Amount	605,850	640,028
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,503	4,660
Accumulated Amortization	(3,489)	(4,597)
Net Carrying Amount	$ 14	$ 63

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets, Net (Amortization Expense by categories) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 41,460	$ 43,106	$ 35,470
Cost of Sales [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	14,134	15,183	15,368
Selling, General and Administrative Expenses [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	26,658	24,840	19,590
Research and Development Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	154	545	512
Other Operating Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 514	$ 2,538	$ 0

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets, Net (Future Amortization Expense) (Details) $ in Thousands	Dec. 28, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,019	$ 40,200
2,020	40,511
2,021	39,658
2,022	38,623
2,023	36,779
After 2,023	$ 526,279

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Accounts Payable and Accrued Liabilities [Abstract]
Salaries and benefits	$ 21,830	$ 25,103
Profit sharing and bonuses	22,912	13,625
Standard Product Warranty Accrual	2,600	2,820	$ 2,764
Deferred Revenue	2,482	1,610
Accrued interest	1,944	8,523
Other	8,722	8,695
Total	$ 60,490	$ 60,376

Debt (Schedule of Long-Term Deb

Debt (Schedule of Long-Term Debt) (Details) - USD ($) $ in Thousands	Dec. 28, 2018	Dec. 29, 2017
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ (16,466)	$ (33,278)
Total debt	925,507	1,609,165
Current portion of long-term debt	(37,500)	(30,469)
Long-term debt	888,007	1,578,696
Loans Payable [Member] | Secured Debt [Member] | Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Long-term debt, gross	304,687	335,157
Loans Payable [Member] | Secured Debt [Member] | Term Loan B (TLB) Facility [Member]
Debt Instrument [Line Items]
Long-term debt, gross	632,286	873,286
Loans Payable [Member] | Secured Debt [Member] | 9.125% Senior Notes due 2023 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	0	360,000
Revolving Credit Facility [Member] | Secured Debt [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 5,000	$ 74,000

Debt (Senior Secured Credit Fac

Debt (Senior Secured Credit Facilities) (Details)	Jul. 10, 2018USD ($)	Nov. 30, 2017	Oct. 27, 2015USD ($)loan_facility	Dec. 28, 2018USD ($)
Debt Instrument [Line Items]
Weighted average interest rate				5.27%
Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	100.00%
Payment for Debt Extinguishment or Debt Prepayment Cost	$ 31,300,000
Senior Notes [Member] | Senior Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Repayment of debt	188,000,000
Secured Debt [Member] | Senior Secured Credit Facilities [Member] | Maximum [Member]
Debt Instrument [Line Items]
First lien net leverage ratio			4.25
Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 200,000,000
Debt maturity date			Oct. 27, 2020
Outstanding borrowings				$ 5,000,000
Remaining borrowing capacity				188,200,000
Outstanding standby letters of credit				$ 6,800,000
Weighted average interest rate				5.01%
Repayment of debt	74,000,000
Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Unused capacity commitment fee			0.175%
Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Unused capacity commitment fee			0.25%
Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member] | Prime Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Spread on variable rate			0.75%
Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member] | Prime Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Spread on variable rate			2.25%
Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Spread on variable rate			1.75%
Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Spread on variable rate			3.25%
Secured Debt [Member] | Loans Payable [Member]
Debt Instrument [Line Items]
Number of additional term loan facilities that may be added (one or more) | loan_facility			1
Secured Debt [Member] | Loans Payable [Member] | Maximum [Member]
Debt Instrument [Line Items]
First lien net leverage ratio			4.25
Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Principle amount			$ 305,000,000
Debt maturity date			Oct. 27, 2021
Weighted average interest rate				5.01%
Maximum leverage ratio			5.50
Adjusted EBITDA to interest expense ratio			2.75
Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | Prime Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Spread on variable rate			0.75%
Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | Prime Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Spread on variable rate			2.25%
Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Spread on variable rate			1.75%
Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Spread on variable rate			3.25%
Secured Debt [Member] | Loans Payable [Member] | Term Loan B (TLB) Facility [Member]
Debt Instrument [Line Items]
Principle amount			$ 632,000,000
Discount percent			1.00%
Debt maturity date			Oct. 27, 2022
Weighted average interest rate				5.39%
Debt fair value				$ 616,000,000
Repayment of debt	$ 114,000,000
Secured Debt [Member] | Loans Payable [Member] | Term Loan B (TLB) Facility [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Spread on variable rate			2.00%
Secured Debt [Member] | Loans Payable [Member] | Term Loan B (TLB) Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Reduction to interest rate margins		1.00%
Spread on variable rate			3.00%
Interest rate floor			1.00%
Secured Debt [Member] | Loans Payable [Member] | Term Loan B (TLB) Facility [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Reduction to interest rate margins		1.00%
Secured Debt [Member] | Swingline Loans [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 15,000,000
Secured Debt [Member] | Standby Letters of Credit [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 25,000,000

Debt (Senior Notes) (Details)

Debt (Senior Notes) (Details) - USD ($)	Jul. 10, 2018	Oct. 27, 2015	Dec. 28, 2018
Debt Instrument [Line Items]
Weighted average interest rate			5.27%
Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	100.00%
Payment for Debt Extinguishment or Debt Prepayment Cost	$ 31,300,000
Senior Notes [Member] | 9.125% Senior Notes due 2023 [Member]
Debt Instrument [Line Items]
Principle amount		$ 360,000,000
Stated interest rate		9.125%	9.125%
Debt maturity date		Nov. 1, 2023
Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Principle amount		$ 305,000,000
Debt maturity date		Oct. 27, 2021
Weighted average interest rate			5.01%
Secured Debt [Member] | Maximum [Member] | Prime Rate [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Spread on variable rate		2.25%
Secured Debt [Member] | Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Spread on variable rate		3.25%
Secured Debt [Member] | Minimum [Member] | Prime Rate [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Spread on variable rate		0.75%
Secured Debt [Member] | Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Spread on variable rate		1.75%

Debt (Long-term Debt Maturity S

Debt (Long-term Debt Maturity Schedule) (Details) $ in Thousands	Dec. 28, 2018USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
2,019	$ 37,500
2,020	42,500
2,021	229,687
2,022	632,286
After 2,023	$ 0

Debt (Debt Issuance Costs and D

Debt (Debt Issuance Costs and Discounts) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017
Term Loan B (TLB) Facility [Member]
Debt Instrument [Line Items]
Losses from of extinguishment of debt	$ 11.4	$ 3.5

Debt (Deferred Financing Fees)

Debt (Deferred Financing Fees) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Deferred Finance Costs [Roll Forward]
Total, Beginning Balance	$ 33,278
Total, Amortization during the period	(49,110)	$ (10,911)	$ (7,278)
Total, Ending Balance	16,466	33,278
Revolving Credit Facility [Member]
Deferred Finance Costs [Roll Forward]
Debt issuance costs, Beginning Balance	2,808	3,800
Debt issuance costs, Amortization during the period	(991)	(992)
Debt issuance costs, Ending Balance	1,817	2,808	3,800
Term Loan And Senior Notes [Member]
Deferred Finance Costs [Roll Forward]
Debt issuance costs, Beginning Balance	26,889	32,096
Debt issuance costs, Financing costs incurred		2,360
Debt issuance costs, Write off of debt issuance costs and unamortized discount	(9,757)	(2,421)
Debt issuance costs, Amortization during the period	(4,419)	(5,146)
Debt issuance costs, Ending Balance	12,713	26,889	32,096
Total, Beginning Balance	33,278	40,837
Total, Financing costs incurred		2,360
Total, Write-off during the period	(11,367)	(3,525)
Total, Amortization during the period	(5,445)	(6,394)
Total, Ending Balance	16,466	33,278	40,837
Term Loan B (TLB) Facility [Member]
Deferred Finance Costs [Roll Forward]
Unamortized discount on TLB Facility, Beginning Balance	6,389	8,741
Unamortized discount on TLB Facility, Financing costs incurred		0
Unamortized discount on TLB Facility, Write-off during the period	(1,610)	(1,104)
Unamortized discount on TLB Facility, Amortization during the period	(1,026)	(1,248)
Unamortized discount on TLB Facility, Ending Balance	3,753	6,389	$ 8,741
Gain (Loss) on Extinguishment of Debt	$ (11,400)	$ (3,500)

Debt (Interest Rate Swaps) (Det

Debt (Interest Rate Swaps) (Details) - USD ($)	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Derivative [Line Items]
Interest expense	$ 99,310,000	$ 63,972,000	$ 68,331,000
Interest Rate Swap 1 [Member]
Derivative [Line Items]
Interest Rate Swap Term	3 years
Notional Amount	$ 200,000,000
Pay Fixed Rate	1.1325%
Receive Current Floating Rate	2.5063%
Fair Value	$ 4,171,000
Interest Rate Swap [Member]
Derivative [Line Items]
Portion of the change in fair value considered ineffective	0	0	0
Interest expense	1,700,000	$ 500,000	$ 100,000
Gain expected to be reclassified into earnings within the next twelve months	$ 2,800,000

Benefit Plans (Narrative) (Deta

Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Defined Contribution And Benefit Plan Disclosure [Line Items]
Net costs recognized	$ 6.8	$ 6	$ 4.6
Defined Benefit Plan, Basis Points	0.50%
Maximum [Member]
Defined Contribution And Benefit Plan Disclosure [Line Items]
Employer matching contribution, percentage	50.00%
Employer matching contribution, percentage of employees' gross pay	6.00%
Legacy Greatbatch 401(k) Plan [Member] | Defined Contribution Plan Cash [Member]
Defined Contribution And Benefit Plan Disclosure [Line Items]
Employer matching contribution, percentage of employees' gross pay			35.00%
Lakes Region Medical 401(k) Plan [Member] | Lake Region Medical 401(k) Plan [Member]
Defined Contribution And Benefit Plan Disclosure [Line Items]
Employer matching contribution, percentage			50.00%

Benefit Plans (Change in Projec

Benefit Plans (Change in Projected Benefit Obligation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Projected benefit obligation at beginning of year	$ 2,608	$ 2,285
Service cost	214	200	$ 173
Interest cost	48	42	36
Plan participants’ contribution	84	75
Actuarial gain	(150)	(90)
Benefits (paid) transferred in, net	42	11
Defined Benefit Plan, Settlement and Curtailment	(619)	0
Foreign currency translation	(24)	107
Projected benefit obligation at end of year	$ 2,203	$ 2,608	$ 2,285

Benefit Plans (Change in Fair V

Benefit Plans (Change in Fair Value of Plan Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	$ 1,358	$ 1,172
Employer contributions (refund)	83	56
Plan participants’ contributions	84	75
Actual loss on plan assets	(11)	0
Benefits transferred in, net	62	0
Defined Benefit Plan, Plan Assets, Payment for Settlement	(619)	0
Foreign currency translation	(11)	55
Fair value of plan assets at end of year	946	1,358
Projected benefit obligation in excess of plan assets at end of year	1,257	1,250
Defined benefit liability classified as other current liabilities	54	32
Defined benefit liability classified as long-term liabilities	1,203	1,218
Accumulated benefit obligation at end of year	$ 1,809	$ 2,189

Benefit Plans (Amount Recognize

Benefit Plans (Amount Recognized in Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Defined Benefit Plan Disclosure [Line Items]
Pre-tax adjustment (gain) loss	$ (232)	$ (53)
Tax benefit	(70)	(23)
Net (gain) loss	(302)	(76)	$ 579
Continuing Operations
Defined Benefit Plan Disclosure [Line Items]
Net (gain) loss occurring during the year	(130)	74
Amortization of losses	(101)	(45)
Prior service cost	1	1
Amortization of prior service cost	(2)	(2)
Pre-tax adjustment (gain) loss	(232)	28
Tax benefit	(70)	(5)
Net (gain) loss	$ (302)	$ 23

Benefit Plans (Amortization to

Benefit Plans (Amortization to be Recognized in Accumulated Other Comprehensive Income) (Details) $ in Thousands	Dec. 28, 2018USD ($)
Defined Benefit Plan [Abstract]
Amortization of net prior service credit	$ 1
Amortization of net loss	$ 5

Benefit Plans (Net Pension Cost

Benefit Plans (Net Pension Costs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 214	$ 200	$ 173
Interest cost	48	42	36
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement	69	0	0
Expected return on assets	(17)	(19)	(18)
Recognized net actuarial loss	33	44	38
Net pension cost	$ 347	$ 267	$ 229

Benefit Plans (Actuarial Valuat

Benefit Plans (Actuarial Valuations) (Details)	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Discount rate	3.10%	2.90%	2.30%
Salary growth	3.20%	3.10%	2.40%
Expected rate of return on assets	1.30%	1.50%	2.00%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	6.00%	3.10%	2.90%
Salary growth	4.10%	3.20%	3.10%
Expected rate of return on assets	1.40%	1.30%	1.50%

Benefit Plans (Plan Assets Comp

Benefit Plans (Plan Assets Components) (Details) - USD ($) $ in Thousands	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 946	$ 1,358	$ 1,172
Insurance Contract [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	946	1,358
Insurance Contract [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Insurance Contract [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	946	1,358
Insurance Contract [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0

Benefit Plans (Estimated Benefi

Benefit Plans (Estimated Benefit Payments Over Next Ten Years) (Details) $ in Thousands	Dec. 28, 2018USD ($)
Defined Benefit Plan, Expected Future Benefit Payment [Abstract]
2,019	$ 104
2,020	121
2,021	124
2,022	134
2,022	145
2024-2028	$ 964

Stock-Based Compensation (Narra

Stock-Based Compensation (Narratives) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2017	Apr. 01, 2016	Sep. 29, 2017	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accelerated compensation cost	$ 2.2	$ 0.5
Restricted Stock and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense tax benefit				$ 3.8	$ 1.9	$ 2.3
Period for recognition				2 years 3 months
Total unrecognized compensation cost				$ 5.8
Fair value of shares vested				$ 9.7	$ 6.4	$ 1.3
Granted (in dollars per share)				$ 52.14	$ 34.18	$ 47.95
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing stock price				$ 76.03
Unrecognized compensation cost related to non-vested stock options				$ 0.5
Period for recognition				1 year 2 months
Expected term (in years)				4 years	4 years 6 months	4 years 7 months 30 days
Risk-free interest rate				2.21%	1.77%	1.49%
Expected dividend yield				0.00%	0.00%	0.00%
Expected volatility				39.00%	37.00%	27.00%
Performance Based Restricted Stock And Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period for recognition				1 year 11 months
Total unrecognized compensation cost				$ 3.3
Fair value of shares vested				$ 9.1		$ 10.5
Granted (in dollars per share)				$ 45.37	$ 31.62	$ 30.83
Expected term (in years)			2 years 11 months
Risk-free interest rate			2.28%
Expected dividend yield				0.00%
Expected volatility			40.00%
2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized				1,350,000
Number of shares available for grant				65,190
2009 Plan [Member] | Restricted Stock and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized				200,000
Number of shares available for grant				7,488
2011 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant				119,866
2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized				1,450,000
Number of shares available for grant				722,766

Stock-Based Compensation (Compo

Stock-Based Compensation (Components of Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	$ 10,470	$ 14,680	$ 8,408
Allocated Share-based Compensation Expense	10,470	14,680	8,408
Income Statement Location, Discontinued Operations [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	414	1,228	302
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	849	748	208
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	9,090	9,893	6,086
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	112	642	337
Other Operating Expenses, net [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	5	2,169	1,475
Stock Options [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	873	1,633	2,455
Restricted Stock And Unit Awards [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	6,024	4,952	1,764
Performance Based Restricted Stock And Restricted Stock Units [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	3,159	6,867	3,887
Continuing Operations
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 10,056	$ 13,452	$ 8,106

Stock-Based Compensation (Weigh

Stock-Based Compensation (Weighted-Average Fair Value and Assumptions) (Details) - Stock Options [Member] - $ / shares	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of options granted	$ 14.89	$ 12.86	$ 8.52
Expected term (in years)	4 years	4 years 6 months	4 years 7 months 30 days
Risk-free interest rate	2.21%	1.77%	1.49%
Expected volatility	39.00%	37.00%	27.00%
Expected dividend yield	0.00%	0.00%	0.00%

Stock-Based Compensation (Stock

Stock-Based Compensation (Stock Option Activity) (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 28, 2018USD ($)$ / sharesshares
Number of Stock Options
Beginning balance (in shares) | shares	931,353
Granted (in shares) | shares	28,447
Exercised (in shares) | shares	(413,317)
Forfeited or expired (in shares) | shares	(23,700)
Ending balance (in shares) | shares	522,783
Vested and expected to vest (in shares) | shares	522,783
Exercisable (in shares) | shares	488,468
Weighted Average Exercise Price
Beginning balance (in dollars per share) | $ / shares	$ 30.89
Granted (in dollars per share) | $ / shares	45.13
Exercised (in dollars per share) | $ / shares	30.02
Forfeited or expired (in dollars per share) | $ / shares	41.28
Ending balance (in dollars per share) | $ / shares	31.88
Vested and expected to vest (in dollars per share) | $ / shares	31.88
Exercisable (in dollars per share) | $ / shares	$ 31.37
Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value
Outstanding, weighted average remaining contractual term	5 years 10 months
Vested and expected to vest, weighted average remaining contractual term	5 years 10 months
Exercisable, weighted average remaining contractual term	5 years 7 months
Outstanding, aggregate intrinsic value | $	$ 23.1
Vested and expected to vest, aggregate intrinsic value | $	23.1
Exercisable, aggregate intrinsic value | $	$ 21.8

Stock-Based Compensation (Exerc

Stock-Based Compensation (Exercise of Stock Option) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Intrinsic value	$ 17,722	$ 13,928	$ 690
Cash received	$ 12,409	$ 19,324	$ 2,821

Stock-Based Compensation (Restr

Stock-Based Compensation (Restricted Stock and Restricted Stock Units) (Details)	12 Months Ended
	Dec. 28, 2018$ / sharesshares
Restricted Stock And Restricted Stock Units Time Based [Member]
Time-Vested and Performance-Vested Restricted Stock Units and Awards
Beginning balance (in shares) | shares	163,431
Granted (in shares) | shares	167,514
Vested (in shares) | shares	(134,423)
Forfeited (in shares) | shares	(54,286)
Ending balance (in shares) | shares	142,236
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 35.96
Granted (in dollars per share) | $ / shares	52.14
Vested (in dollars per share) | $ / shares	38.88
Forfeited (in dollars per share) | $ / shares	42.44
Ending balance (in dollars per share) | $ / shares	$ 49.78
Performance Based Restricted Stock And Restricted Stock Units [Member]
Time-Vested and Performance-Vested Restricted Stock Units and Awards
Beginning balance (in shares) | shares	469,889
Granted (in shares) | shares	159,669
Vested (in shares) | shares	(161,674)
Forfeited (in shares) | shares	(180,750)
Ending balance (in shares) | shares	287,134
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 32.37
Granted (in dollars per share) | $ / shares	45.37
Vested (in dollars per share) | $ / shares	35.28
Forfeited (in dollars per share) | $ / shares	35.24
Ending balance (in dollars per share) | $ / shares	$ 36.15

Other Operating Expenses (Detai

Other Operating Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Operating Costs and Expenses [Abstract]
Total other operating expenses	$ 16,065	$ 36,438	$ 60,413
Other Cost and Expense, Operating, Including Discontinued Operations	16,065	36,438	60,413
Consolidation and optimization initiatives [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring Reserve	1,870	1,308
Restructuring charges	14,557
Payments for Restructuring	13,481
Operating Costs and Expenses [Abstract]
Total other operating expenses	844	12,803	25,510
Acquisition and integration costs [Member]
Operating Costs and Expenses [Abstract]
Total other operating expenses	0	10,870	28,112
Asset dispositions, severance and other [Member]
Operating Costs and Expenses [Abstract]
Total other operating expenses	1,508	6,874	6,791
Strategic reorganization and alignment [Member]
Operating Costs and Expenses [Abstract]
Total other operating expenses	10,624	5,891	0
Manufacturing Alignment To Support Growth [Member]
Operating Costs and Expenses [Abstract]
Total other operating expenses	3,089	0	$ 0
Accelerated Depreciation And Asset Write Offs [Member] | Consolidation and optimization initiatives [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring Reserve	0	0
Restructuring charges	514
Payments for Restructuring	0
Other Restructuring [Member] | Consolidation and optimization initiatives [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring Reserve	202	0
Restructuring charges	10,231
Payments for Restructuring	10,029
Severance And Retention [Member] | Consolidation and optimization initiatives [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring Reserve	1,668	$ 1,308
Restructuring charges	3,812
Payments for Restructuring	3,452
Investments in Capacity and Capabilities [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring Reserve, Settled without Cash	514
Investments in Capacity and Capabilities [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring Reserve, Settled without Cash	514
Investments in Capacity and Capabilities [Member] | Other Restructuring [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring Reserve, Settled without Cash	0
Investments in Capacity and Capabilities [Member] | Severance And Retention [Member]
Other Operating Income Expense Detail [Line Items]
Restructuring Reserve, Settled without Cash	$ 0

Other Operating Expenses (Narra

Other Operating Expenses (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Restructuring Cost and Reserve [Line Items]
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	$ 120,931	$ (20,408)	$ (18,917)
Spinoff [Member]
Restructuring Cost and Reserve [Line Items]
Leadership transition costs	5,300
Asset Dispositions Severance And Other [Member]
Restructuring Cost and Reserve [Line Items]
Leadership transition costs	4,400
Strategic reorganization and alignment [Member]
Restructuring Cost and Reserve [Line Items]
Capital investments expended	16,500
Strategic reorganization and alignment [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Total expense expected	28,000
Costs expected to result in cash outlays	16,000
Strategic reorganization and alignment [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Total expense expected	30,000
Costs expected to result in cash outlays	20,000
Manufacturing Alignment To Support Growth [Member]
Restructuring Cost and Reserve [Line Items]
Capital investments expended	3,400
Manufacturing Alignment To Support Growth [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Total expense expected	9,000
Expected capital expenditures	4,000
Manufacturing Alignment To Support Growth [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Total expense expected	11,000
Expected capital expenditures	6,000
Acquisition And Integration Costs [Member] | Lake Region Medical [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition integration related costs accrued	400
AS&O Business [Member] | Discontinued Operations, Held-for-sale [Member]
Restructuring Cost and Reserve [Line Items]
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	$ 120,931	$ (20,408)	$ (18,917)

Other Operating Expenses (Chang

Other Operating Expenses (Changes in Accrued Liabilities) (Details) - Consolidation and optimization initiatives [Member] $ in Thousands	12 Months Ended
	Dec. 28, 2018USD ($)
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	$ 1,308
Restructuring charges	14,557
Cash payments	(13,481)
Restructuring Reserve, Ending balance	1,870
Severance And Retention [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	1,308
Restructuring charges	3,812
Cash payments	(3,452)
Restructuring Reserve, Ending balance	1,668
Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning balance	0
Restructuring charges	10,231
Cash payments	(10,029)
Restructuring Reserve, Ending balance	$ 202

Income Taxes (Narratives) (Deta

Income Taxes (Narratives) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Tax benefit from revaluation of net deferred tax liabilities	$ 56.5
Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Undistributed Accumulated Earnings Of Foreign Subsidiary		$ 147.5
Provisional income tax expense	14.7	$ 14.7
Reasonably possible reduction within next 12 months	0.9
Unrecognized tax benefit	$ 5.3

Income Taxes (Income Before Inc

Income Taxes (Income Before Income Tax Domestic And Foreign) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Income Tax Disclosure [Line Items]
Income (loss) from continuing operations before income taxes	$ 61,116	$ 49,259	$ 28,165
UNITED STATES [Member]
Income Tax Disclosure [Line Items]
Income (loss) from continuing operations before income taxes	(4,273)	306	(12,547)
International [Member]
Income Tax Disclosure [Line Items]
Income (loss) from continuing operations before income taxes	$ 65,389	$ 48,953	$ 40,712

Income Taxes (Provision Benefit

Income Taxes (Provision Benefit of Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Non-deductible transaction costs			$ 1,012
Current:
Federal	$ 80	$ (1,558)	(8,327)
State	166	(29)	149
International	9,490	8,539	7,230
Total	9,736	6,952	(948)
Deferred:
Federal	6,610	(45,114)	5,457
State	103	(295)	527
International	(2,366)	629	(1,749)
Total	61,126	(59,212)	(7,350)
Effective tax rate	14,083	(37,828)	$ 3,287
Non-deductible transaction costs, percent			3.60%
Continuing Operations
Deferred:
Total	$ 4,347	$ (44,780)	$ 4,235

Income Taxes (Effect Tax Rate R

Income Taxes (Effect Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Income Tax Disclosure [Abstract]
Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Undistributed Accumulated Earnings Of Foreign Subsidiary		$ 147,500
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory rate	$ 12,834	17,240	$ 9,858
Federal tax credits	(1,700)	(1,674)	(1,570)
Foreign rate differential	(6,040)	(12,934)	(9,665)
Uncertain tax positions	147	34	219
State taxes, net of federal benefit	975	(543)	(311)
Valuation allowance	(567)	1,030	1,273
Change in tax rates	0	0	(270)
Change in unremitted earnings assertion	11	(39,394)
Change in tax law (Internal Revenue Code §987)	0	0	2,630
Other	(2,050)	(3,058)	(1,397)
Effective tax rate	$ 14,083	$ (37,828)	$ 3,287
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory rate	21.00%	35.00%	35.00%
Federal tax credits	(2.80%)	(3.40%)	(5.60%)
Foreign rate differential	(9.90%)	(26.30%)	(34.30%)
Uncertain tax positions	0.20%	0.10%	0.80%
State taxes, net of federal benefit	1.60%	(1.10%)	(1.10%)
Valuation allowance	(0.90%)	2.10%	4.50%
Change in tax rates	0.00%	0.00%	(1.00%)
Change in unremitted earnings assertion	0.00%	(80.00%)
Change in tax law (Internal Revenue Code §987)	0.00%	0.00%	9.30%
Other	(3.30%)	(6.20%)	(5.00%)
Effective tax rate	23.00%	(76.80%)	11.70%
Non-deductible transaction costs			$ 1,012
Non-deductible transaction costs, percent			3.60%
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent	$ 10,473	$ 1,471	$ 1,508
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent	17.10%	3.00%	5.40%

Income Taxes (Deferred Tax Asse

Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($)	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017
Income Tax Disclosure [Abstract]
Deferred Tax Liabilities, Noncurrent assets of discontinued operations held for sale	$ 0	$ 701,000
Deferred Tax Assets, Gross, Noncurrent	3,937,000	4,152,000
Deferred Tax Liabilities, Gross, Noncurrent	203,910,000	145,364,000
Deferred Income Tax Liabilities, Net	(203,910,000)	(140,964,000)
Deferred Tax Liabilities, Noncurrent liabilities of discontinued operations held for sale	0	(4,400,000)
Components of Deferred Tax Assets and Liabilities [Abstract]
Net operating loss carryforwards	18,088,000	107,005,000
Tax credit carryforwards	24,593,000	28,215,000
Inventories	3,408,000	4,956,000
Accrued expenses	39,000	3,815,000
Stock-based compensation	2,340,000	5,531,000
Gross deferred tax assets	48,468,000	149,522,000
Less valuation allowance	(34,339,000)	(36,480,000)
Net deferred tax assets	14,129,000	113,042,000
Property, plant and equipment	(9,445,000)	(27,547,000)
Intangible assets	(198,648,000)	(219,576,000)
Convertible subordinated notes	0	(806,000)
Other	(6,009,000)	(6,325,000)
Gross deferred tax liabilities	(214,102,000)	(254,254,000)
Net deferred tax liability	$ (199,973,000)	$ (141,212,000)

Income Taxes (Deferred Tax As_2

Income Taxes (Deferred Tax Assets and Liabilities Current Noncurrent) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 28, 2018	Dec. 28, 2018	Dec. 29, 2017
Income Tax Disclosure [Abstract]
Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Undistributed Accumulated Earnings Of Foreign Subsidiary			$ 147,500,000
Components of Deferred Tax Assets and Liabilities [Abstract]
Noncurrent deferred tax asset		$ 3,937,000	3,451,000
Noncurrent deferred tax liability		(203,910,000)	(140,964,000)
Net deferred tax liability		(199,973,000)	(141,212,000)
Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Income Tax Expense (Benefit)		14,700,000	$ 14,700,000
Tax benefit from revaluation of net deferred tax liabilities		56,500,000
Tax Cuts And Jobs Act Of 2017, Measurement Period Adjustment, Transition Tax		18,900,000
Tax Cuts And Jobs Act Of 2017, Measurement Period Adjustment, Transition Tax Adjustment	$ 4,200,000
Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Measurement Period Adjustments, Provisional Income Tax (Expense) Benefit		$ 60,700,000
Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Provisional Income Tax (Expense) Benefit, Adjustment	$ 4,200,000

Income Taxes (Income Tax Carry

Income Taxes (Income Tax Carry Forward) (Details) $ in Millions	Dec. 28, 2018USD ($)
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 39.1
Federal [Member] | Foreign Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax Credit	17
International [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss	31.1
US and State [Member] | Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax Credit	3.6
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss	130.6
State [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax Credit	$ 6.8

Income Taxes (Unrecognized Tax

Income Taxes (Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance, beginning of year	$ 12,088	$ 10,561	$ 9,271
Additions based upon tax positions related to the current year	300	3,833	1,450
Reductions as a result of a lapse of applicable statute of limitations	0	(510)	0
Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change In Tax Rate, Revaluation Of Unrecognized Tax Benefit	0	1,782	0
Reductions related to prior period tax returns	(75)	(14)	(240)
Reductions relating to business combinations	0	0	(400)
Reductions relating to settlements with tax authorities	(98)	0	0
Unrecognized Tax Benefits, Decrease Relating to Divestiture	(6,846)	0	0
Balance, end of year	$ 5,369	$ 12,088	$ 10,561

Commitments and Contingencies_2

Commitments and Contingencies (Narratives) (Details)	Jan. 14, 2019USD ($)	Jan. 26, 2016USD ($)patent	Dec. 28, 2018USD ($)	Dec. 29, 2017USD ($)	Dec. 30, 2016USD ($)
Gain Contingencies [Line Items]
Gain on litigation settlement		$ 0
Expenses related to license agreements			$ 852,347,000	$ 782,070,000	$ 737,823,000
Standard product warranty description			The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship.
Self Insurance Reserve			$ 4,200,000	5,800,000
Other Noncurrent Liabilities [Member]
Gain Contingencies [Line Items]
Environmental matter accruals				1,000,000
Positive Outcome of Litigation [Member]
Gain Contingencies [Line Items]
Number of patents found infringed upon | patent		3
Settlement amount		$ 37,500,000
Royalty [Member]
Gain Contingencies [Line Items]
Expenses related to license agreements			$ 1,600,000	$ 1,100,000	$ 1,000,000
Subsequent Event [Member] | Positive Outcome of Litigation [Member]
Gain Contingencies [Line Items]
Settlement amount	$ 22,200,000

Commitments and Contingencies_3

Commitments and Contingencies (Change in Product Warranty Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning balance	$ 2,820	$ 2,764
Additions to warranty reserve, net of reversals	620	917
Warranty claims settled	(840)	(861)
Ending balance	$ 2,600	$ 2,820

Commitments and Contingencies_4

Commitments and Contingencies (Operating Lease Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Operating lease expense	$ 10,753	$ 14,320	$ 12,127

Commitments and Contingencies_5

Commitments and Contingencies (Minimum Future Estimated Operating Lease Expense) (Details) $ in Thousands	Dec. 28, 2018USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,018	$ 8,562
2,019	7,290
2,020	7,348
2,021	5,269
2,022	5,112
After 2,022	$ 14,589

Commitments and Contingencies_6

Commitments and Contingencies (Foreign Currency Contracts) (Details) $ in Thousands	12 Months Ended
	Dec. 28, 2018USD ($)	Dec. 29, 2017USD ($)	Dec. 30, 2016USD ($)
Foreign Currency Cash Flow Hedges [Abstract]
Increase (decrease) in sales	$ (758)	$ 1,327	$ 0
Increase (decrease) in cost of sales	(944)	84	3,516
Ineffective portion of change in fair value	$ 0	$ 0	$ 0
Derivative [Line Items]
Description of Types of Foreign Currency Cash Flow Hedging Instruments Used	The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations
Terminated FX Contract [Member]
Derivative [Line Items]
Loss on termination of foreign currency contract	$ (700)
FX Contract 1 [Member]
Derivative [Line Items]
Notional Amount	$ 12,621
Start Date	Jan. 2, 2019
End Date	Jun. 28, 2019
$/Foreign Currency	1.1686
FX Contract 2 [Member]
Derivative [Line Items]
Notional Amount	$ 10,991
Start Date	Jan. 2, 2019
End Date	Jun. 28, 2019
$/Foreign Currency	0.0523
FX Contract 3 [Member]
Derivative [Line Items]
Notional Amount	$ 10,535
Start Date	Jan. 2, 2019
End Date	Jun. 28, 2019
$/Foreign Currency	1.1705
FX Contract 4 [Member]
Derivative [Line Items]
Notional Amount	$ 11,019
Start Date	Jan. 2, 2019
End Date	Jun. 28, 2019
$/Foreign Currency	0.0483
FX Contract 5 [Member]
Derivative [Line Items]
Notional Amount	$ 10,499
Start Date	Jul. 1, 2019
End Date	Dec. 31, 2019
$/Foreign Currency	0.0500
Accrued Expenses [Member] | FX Contract 1 [Member]
Derivative [Line Items]
Fair Value	$ (149)
Accrued Expenses [Member] | FX Contract 2 [Member]
Derivative [Line Items]
Fair Value	(494)
Accrued Expenses [Member] | FX Contract 3 [Member]
Derivative [Line Items]
Fair Value	(141)
Accrued Expenses [Member] | FX Contract 4 [Member]
Derivative [Line Items]
Fair Value	(316)
Accrued Expenses [Member] | FX Contract 5 [Member]
Derivative [Line Items]
Fair Value	$ 368

Earnings (Loss) Per Share (Deta

Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 29, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent									$ 47,033	$ 87,087	$ 24,878
Income (Loss) from Continuing Operations, Per Diluted Share									$ 1.44	$ 2.72	$ 0.80
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share									$ 3.71	$ (0.64)	$ (0.61)
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent									$ 120,931	$ (20,408)	$ (18,917)
Net income (loss)	$ 19,196	$ (8,303)	$ 23,056	$ 13,084	$ 54,698	$ 19,882	$ 9,559	$ 2,948	$ 167,964	$ 66,679	$ 5,961
Denominator for basic EPS:
Weighted average shares outstanding									32,136	31,402	30,778
Effect of dilutive securities stock options, restricted stock and restricted stock units									460	654	195
Denominator for diluted EPS									32,596	32,056	30,973
Income (Loss) from Continuing Operations, Per Basic Share									$ 1.46	$ 2.77	$ 0.81
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share									3.76	(0.65)	(0.61)
Basic (in dollars per share)	$ 0.59	$ (0.26)	$ 0.72	$ 0.41	$ 1.73	$ 0.63	$ 0.31	$ 0.10	5.23	2.12	0.19
Diluted (in dollars per share)	$ 0.58	$ (0.26)	$ 0.70	$ 0.40	$ 1.69	$ 0.62	$ 0.30	$ 0.09	$ 5.15	$ 2.08	$ 0.19

Earnings (Loss) Per Share (Anti

Earnings (Loss) Per Share (Antidilutive Securities) (Details) - shares	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]
Time-vested stock options, restricted stock and restricted stock units	0	1,000	1,000
Performance-vested stock options and restricted stock units	144	285	357

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Defined Benefit Plan Liability
Defined Benefit Plan Liability, Beginning	$ (1,422)	$ (1,475)
Net defined benefit plan adjustments	232	53
Defined Benefit Plan Liability, Ending	(295)	(1,422)	$ (1,475)
Cash Flow Hedges
Cash Flow Hedges, Beginning	3,418	1,420
Unrealized gain on cash flow hedges	1,904	3,707
Realized gain on foreign currency hedges	(186)	(1,243)
Realized gain on interest rate swap hedges	(1,697)	(466)
Cash Flow Hedges, End	3,439	3,418	1,420
Foreign Currency Translation Adjustment
Foreign Currency Translation Adjustment, Beginning	50,200	(15,660)
Foreign currency translation loss	(19,925)	65,860
Foreign Currency Translation Adjustment, End	30,539	50,200	(15,660)
Total Pre-Tax Amount
Total Pre-Tax Amount, Beginning	52,196	(15,715)
Unrealized gain on cash flow hedges	1,904	3,707
Realized gain on foreign currency hedges	(186)	(1,243)
Realized gain on interest rate swap hedges	(1,697)	(466)
Net defined benefit plan adjustments	232	53
Foreign currency translation loss	(19,925)	65,860
Total Pre-Tax Amount, End	33,683	52,196	(15,715)
Tax
Tax, Beginning	(17)	(285)
Unrealized gain on cash flow hedges	(400)	(353)
Realized gain on foreign currency hedges	39	435
Realized gain on interest rate swap hedges	356	163
Net defined benefit plan adjustments	70	23
Foreign currency translation loss	0	0
Tax, End	(679)	(17)	(285)
Net-of-Tax Amount
Net-of-Tax Amount, Beginning	52,179	(16,000)
Unrealized gain on cash flow hedges	1,504	3,354
Realized gain on foreign currency hedges	(147)	(808)
Realized gain on interest rate swap hedges	(1,341)	(303)
Net defined benefit plan adjustments	302	76	(579)
Foreign currency translation gain (loss)	(19,925)	65,860	(19,269)
Net-of-Tax Amount, End	33,004	52,179	$ (16,000)
Accumulated Other Comprehensive Income, Defined Benefit Plan Liability, Reclassification To Earnings	895
Accumulated Other Comprehensive Income, Reclassification To Earnings, Foreign Currency Translation Adjustment	264
Accumulated Other Comprehensive Income, Defined Benefit Plan Liability, Reclassification To Earnings, Net Of Tax	600
Accumulated Other Comprehensive Income, Reclassification To Earnings, Total Pre-Tax Amount	1,159
Accumulated Other Comprehensive Income, Reclassification to Earnings, Tax	(261)
Accumulated Other Comprehensive Income, Reclassification To Earnings, Net of Tax	898
Tax Cuts and Jobs Act of 2017, Reclassification from AOCI to Retained Earnings, Tax Effect	(466)
Continuing Operations
Defined Benefit Plan Liability
Net defined benefit plan adjustments	232	(28)
Total Pre-Tax Amount
Net defined benefit plan adjustments	232	(28)
Tax
Net defined benefit plan adjustments	70	5
Net-of-Tax Amount
Net defined benefit plan adjustments	$ 302	$ (23)

Fair Value Measurements (Narrat

Fair Value Measurements (Narratives) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Equity method investment	$ 15,148	$ 13,800
Net gains on equity method investments	$ (5,623)	$ (3,685)	$ (737)
Chinese Venture Capital Fund [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of ownership interest	6.70%

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-marketable Equity Securities	$ 7,667	$ 7,008
Net gains on equity method investments	(5,623)	(3,685)	$ (737)
Equity Method Investment, Other than Temporary Impairment		5,250	1,570
Debt and Equity Securities, Realized Gain (Loss)	(5,623)	1,565	$ 833
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	732	861
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	732	861
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	0	0
Interest Rate Swap [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap	4,171	4,279
Interest Rate Swap [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap	0	0
Interest Rate Swap [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap	4,171	4,279
Interest Rate Swap [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap	$ 0	$ 0

Fair Value Measurements (Asse_2

Fair Value Measurements (Assets and Liabilities Measured on Non-recurring Basis) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investments	$ 22,815	$ 20,808
Equity method investment	15,148	13,800
Non-marketable Equity Securities	$ 7,667	$ 7,008

Segment and Geographic Inform_3

Segment and Geographic Information (Narrative) (Details)	12 Months Ended
	Dec. 28, 2018Segment
Segment Reporting [Abstract]
Number of Reportable Segments	2

Segment and Geographic Inform_4

Segment and Geographic Information (Sales by Product Lines) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 29, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales	$ 303,034	$ 305,088	$ 314,464	$ 292,426	$ 302,260	$ 286,168	$ 280,916	$ 266,736	$ 1,215,012	$ 1,136,080	$ 1,075,502
Medical Segment [Member] | Operating Segments [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales									1,162,036	1,079,112	1,033,823
Medical Segment [Member] | Cardio And Vascular [Member] | Operating Segments [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales									585,464	530,831	484,891
Medical Segment [Member] | Cardiac/Neuromodulation [Member] | Operating Segments [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales									443,347	428,275	439,375
Medical Segment [Member] | Advanced Surgical, Orthopaedics, and Portable Medical [Member] | Operating Segments [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales									133,225	120,006	109,557
Non-Medical Segment [Member] | Operating Segments [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales									$ 52,976	$ 56,968	$ 41,679

Segment and Geographic Inform_5

Segment and Geographic Information (Significant Customers) (Details) - customer	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Revenue, Major Customer [Line Items]
Number of Customers	4
Entity-Wide Revenue, Major Customer, Percentage	52.00%	53.00%	57.00%
Entity Wide Accounts Receivable, Major Customer, Percentage	49.00%	52.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Revenue, Major Customer [Line Items]
Number of Customers	4	4	4
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Customer A [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	21.00%	22.00%	24.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Customer B [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	19.00%	20.00%	21.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Customer C [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	12.00%	11.00%	12.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Number of Customers	4	4
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer A [Member]
Revenue, Major Customer [Line Items]
Entity Wide Accounts Receivable, Major Customer, Percentage	11.00%	11.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer B [Member]
Revenue, Major Customer [Line Items]
Entity Wide Accounts Receivable, Major Customer, Percentage	18.00%	21.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer C [Member]
Revenue, Major Customer [Line Items]
Entity Wide Accounts Receivable, Major Customer, Percentage	20.00%	20.00%
Medical Segment [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer [Member] | Customer A [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	22.00%
Medical Segment [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer [Member] | Customer B [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	19.00%
Medical Segment [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer [Member] | Customer C [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	12.00%
Medical Segment [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer [Member] | Customer D [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	0.00%
Medical Segment [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer [Member] | All Other Customers [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	47.00%
Non-Medical Segment [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer [Member] | Customer A [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	0.00%
Non-Medical Segment [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer [Member] | Customer B [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	0.00%
Non-Medical Segment [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer [Member] | Customer C [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	0.00%
Non-Medical Segment [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer [Member] | Customer D [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	28.00%
Non-Medical Segment [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer [Member] | All Other Customers [Member]
Revenue, Major Customer [Line Items]
Entity-Wide Revenue, Major Customer, Percentage	72.00%

Segment and Geographic Inform_6

Segment and Geographic Information (Reconciliation of Segment Information) (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Segment Reporting Information [Line Items]
Operating income as reported	$ 155,555	$ 125,649	$ 92,923
Unallocated other income (expense), net	(94,439)	(76,390)	(64,758)
Income from continuing operations before taxes	61,116	49,259	28,165
Total depreciation and amortization	81,538	81,183	72,868
Total assets	2,326,681	2,848,345
Expenditures for tangible long-lived assets, excluding acquisitions	41,298	30,340	36,716
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income as reported	239,590	208,547	171,614
Total depreciation and amortization	73,286	74,989	67,874
Total assets	2,240,377	2,741,298
Expenditures for tangible long-lived assets, excluding acquisitions	35,188	21,557	28,465
Operating Segments [Member] | Medical Segment [Member]
Segment Reporting Information [Line Items]
Operating income as reported	224,893	197,212	170,101
Total depreciation and amortization	71,922	72,314	65,528
Total assets	2,186,565	2,687,227
Expenditures for tangible long-lived assets, excluding acquisitions	34,615	20,896	27,014
Operating Segments [Member] | Non-Medical Segment [Member]
Segment Reporting Information [Line Items]
Operating income as reported	14,697	11,335	1,513
Total depreciation and amortization	1,364	2,675	2,346
Total assets	53,812	54,071
Expenditures for tangible long-lived assets, excluding acquisitions	573	661	1,451
Unallocated Amount to Segment [Member]
Segment Reporting Information [Line Items]
Operating income as reported	(84,035)	(82,898)	(78,691)
Total depreciation and amortization	8,252	6,194	4,994
Total assets	86,304	107,047
Expenditures for tangible long-lived assets, excluding acquisitions	$ 6,110	$ 8,783	$ 8,251

Segment and Geographic Inform_7

Segment and Geographic Information (Sales by Geographic Information) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 29, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Segment Reporting, Revenue Reconciling Item [Line Items]
Concentration risk percentage									52.00%	53.00%	57.00%
Total sales	$ 303,034	$ 305,088	$ 314,464	$ 292,426	$ 302,260	$ 286,168	$ 280,916	$ 266,736	$ 1,215,012	$ 1,136,080	$ 1,075,502
UNITED STATES [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales									687,259	662,133	625,670
PUERTO RICO [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales									146,500	140,184	162,343
Rest Of World [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales									319,209	278,399	233,988
COSTA RICA
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales									$ 62,044	$ 55,364	$ 53,501

Segment and Geographic Inform_8

Segment and Geographic Information (Long lived Tangible Assets by Region) (Details) - USD ($) $ in Thousands	Dec. 28, 2018	Dec. 29, 2017
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	$ 231,269	$ 235,180
UNITED STATES [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	151,851	157,808
MEXICO
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	34,606	28,985
IRELAND
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	32,190	33,992
Rest Of World [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	$ 12,622	$ 14,395

Quarterly Sales and Earnings _3

Quarterly Sales and Earnings Data - Unaudited (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 29, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Sales	$ 303,034	$ 305,088	$ 314,464	$ 292,426	$ 302,260	$ 286,168	$ 280,916	$ 266,736	$ 1,215,012	$ 1,136,080	$ 1,075,502
Gross Profit	88,445	91,923	98,765	83,532	93,621	89,186	89,175	82,028	362,665	354,010	337,679
Net income (loss)	$ 19,196	$ (8,303)	$ 23,056	$ 13,084	$ 54,698	$ 19,882	$ 9,559	$ 2,948	$ 167,964	$ 66,679	$ 5,961
Basic (in dollars per share)	$ 0.59	$ (0.26)	$ 0.72	$ 0.41	$ 1.73	$ 0.63	$ 0.31	$ 0.10	$ 5.23	$ 2.12	$ 0.19
Earnings Per Share, Diluted	$ 0.58	$ (0.26)	$ 0.70	$ 0.40	$ 1.69	$ 0.62	$ 0.30	$ 0.09	$ 5.15	$ 2.08	$ 0.19

Valuation and Qualifying Acco_2

Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 28, 2018		Dec. 29, 2017		Dec. 30, 2016
SEC Schedule, 12-09, Allowance, Credit Loss [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period		$ 536		$ 475		$ 639
Charged to Costs & Expenses		169		194		(90)
Charged to Other Accounts	[1]	(2)		0		0	[2]
Deductions	[3]	111		133		74
Balance at End of Period		592		536		475
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period		36,480		35,391		39,171
Charged to Costs & Expenses	[4]	0		3,284		641
Charged to Other Accounts	[1]	(170)		0	[2]	(5,135)	[2]
Deductions	[5]	1,971	[3]	2,195		714
Balance at End of Period		$ 34,339		$ 36,480		$ 35,391
[1]	(4) Accounts written off.
[2]	(3) Amount represents measurement-period adjustments related to the acquisition of LRM.
[3]	(2) Includes foreign currency translation effect
[4]	Valuation allowance recorded in the provision for income taxes for certain net operating losses and tax credits. The decrease in 2018 includes the impact of the divestiture of the AS&O Product Lines. The increase in 2017 includes the impact of the adoption of the Tax Reform Act, which increased the value of our state deferred tax assets to which a corresponding valuation allowance was recorded.
[5]	Includes return to provision adjustments for prior years.